UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

______________________

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

______________________

 

Date of Report (Date of earliest event reported):  January 26, 2017

 

Panther Biotechnology Inc.

(Exact Name of Registrant as Specified in its Charter)

______________________________________________________________________________

 

Nevada 000-55074 33-1221758
(State of Incorporation) (Commission File Number) (IRS Employer Identification No.)

 

1517 San Jacinto Street, Houston, Texas 77002

(Address of principal executive offices)

 

Registrant’s telephone number, including area code:  (713) 652-3937

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

     
 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

The information in Item 2.01 below regarding the One Exam Exchange Agreement, Secured Note, Security and Pledge Agreement, Consulting Agreement (each as defined below) and the Lock-Up Agreement, is incorporated in this Item 1.01 by reference.

 

Item 2.01. Completion of Acquisition or Disposition of Assets.

 

One Exam Acquisition

 

On January 26, 2017, Panther Biotechnology, Inc. (“ Panther ”, the “ Company ”, “ we ” and “ us ”) consummated the transactions contemplated by a Share Exchange Agreement (the “ One Exam Exchange Agreement ”), by and between the Company, One Exam Prep LLC (“ One Exam ”), and the sole member of One Exam, Rob Estell. In connection with the closing of the transactions contemplated by the One Exam Exchange Agreement (the “ One Exam Exchange ”), we acquired 100% of the outstanding membership interests of One Exam from Mr. Estell in consideration for the Secured Note (defined below). The amount owed under the Secured Note is secured by a Security and Pledge Agreement, providing Mr. Estell a first priority security interest in all of the membership interests of One Exam, and allowing him to take over control and ownership of One Exam if we default in our obligations under the Secured Note. The One Exam Exchange has an effective date of January 1, 2017. The One Exam Share Exchange included standard and customary representations, warranties and indemnification rights.

 

As additional consideration for agreeing to the terms of the transaction, we agreed to issue Mr. Estell up to 1,000,000 shares of restricted common stock of the Company, as an earn-out, with shares being issued in fiscal 2017 and/or fiscal 2018 (up to a maximum of 1,000,000 in aggregate for both years (the “ Earn-Out Shares ”)), based on the following calculation: (a) total annual revenue of One Exam (for the years ended December 31, 2017 and 2018, as applicable) minus $1,000,000, divided by three, (b) plus total net profit of One Exam minus $100,000, multiplied by three, multiplied by (c) 0.30.

 

One Exam is in the business of exam preparation with a focus on construction training and certification. One Exam offers eLearning courses and weekly training classes and certification in a wide variety of topics for contractors with continuing education in 22 states with a goal of servicing all 50 states. One Exam owns over 70 domains pertaining to contractor licensing and continuing education throughout the United States. One Exam has written dozens of courses which are offered both in an online e-learning setting or in a classroom.

 

The Non-Recourse Secured Convertible Promissory Note (the “ Secured Note ”) provided to Mr. Estell at closing, evidences the principal amount of $300,000 owed to Mr. Estell, which does not accrue interest. Beginning on the first business day which falls thirty days after the earlier of (a) January 20, 2018; and (b) the date we determine in our sole discretion, and continuing month to month thereafter, a portion of the principal amount of the Secured Note equal to the lesser of (A) ten percent (10%) of the total trading volume of our common stock for the thirty (30) days prior to such applicable date; and (B) such number of shares of common stock as equals 4.99% of our then outstanding shares of common stock, multiplied by $0.50 per share, automatically converts into common stock. Additionally, on the first business day following January 20, 2019, the remaining balance of the Secured Note converts into common stock at a conversion price of $0.50 per share. If we fail to comply with any of the provisions of the Secured Note, Mr. Estell’s sole remedy is to take back ownership of the membership interests representing 100% of the ownership of One Exam. The Secured Note contains standard and customary events of default and may be prepaid at any time without penalty. Mr. Estell also entered into a Lock-Up Agreement with us in connection with the closing.

 

As part of the One Exam Exchange, we entered into a Consulting Agreement with Mr. Estell. The Consulting Agreement continues until December 31, 2020, terminable by either party with 90 days prior notice at any time, or 10 days’ notice by us upon the material breach of any term of the Consulting Agreement by Mr. Estell. We agreed to pay Mr. Estell compensation of $1,500 per week during the first year of the term; $1,575 per week during the second year of the term; and $1,654 per week during the third year of the term and Mr. Estell agreed to customary confidentiality and work made for hire terms in the agreement. We also agreed that Mr. Estell would be paid a $60,000 signing bonus, payable in four installments of $15,000 each on April 30, 2017, May 30, 2017, June 30, 2017 and July 30, 2017, and that Mr. Estell could earn a bonus on June 30th and December 31st, of each year during the term of the agreement, equal to (a) total revenue generated by One Exam and other related companies and assets we may acquire in the future, less (i) $500,000, less (ii) 50% of the total revenue for the prior annual period of any related companies and assets we may acquire in the future, (b) divided by 100 (rounded down to the nearest $250,000 increment); plus (x) total gross profit generated by One Exam and other related companies and assets we may acquire in the future, less (i) $37,500, less (ii) 50% of the total gross profit for the prior annual period of any related companies and assets we may acquire in the future; (y) divided by 100 (rounded down to the nearest $25,000 increment)(the “ Bonus ”). We are required to calculate the Bonus as soon as practicable after each June 30th and December 31st, and pay the Bonus due promptly after such calculation is made. In the event that the revenue or gross profit calculation above is negative, we shall decrease the applicable Bonus, provided that the Bonus may not be less than $0, provided further that any negative Bonus calculation for any period ending June 30th, carries over and adjusts downward any positive Bonus for any period ending December 31st.

 

* * * * * *

 

 

 

  2  
 

 

The foregoing descriptions of the One Exam Exchange Agreement, Secured Note, Security and Pledge Agreement, Consulting Agreement and Lock-Up Agreement, do not purport to be complete and are qualified in their entirety by reference to the One Exam Exchange Agreement, Secured Note, Security and Pledge Agreement and Consulting Agreement, copies of which are attached as Exhibits 2.1, 10.1, 10.2, and 10.3, hereto and incorporated by reference herein as Exhibit 10.4, respectively, to this Current Report on Form 8-K, and incorporated herein by reference.

 

Item 2.03 Creation of a Direct Financial Obligation or an Obligation Under an Off-Balance Sheet Arrangement of a Registrant.

 

See the discussions under Item 1.01 above with respect to the Secured Note and Consulting Agreement, which are incorporated in this Item 2.03 in its entirety, by reference.

 

Item 3.02 Unregistered Sales of Equity Securities

 

In connection with the closing of the One Exam Share Exchange, we issued the Secured Note to Mr. Estell (which note is convertible into shares of our common stock) and agreed to issue up to 1,000,000 Earn-Out Shares.

 

The Company claims an exemption from registration pursuant to Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933, as amended (the “ Securities Act ”), for the offer and sale of the Secured Note and Earn-Out Shares, described above in Item 2.01 , due to the fact that the foregoing offers and sales did not involve a public offering, the recipient took the securities for investment and not resale, the Company has taken appropriate measures to restrict transfer, and the recipient (a) is an “ accredited investor, ” and (b) has access to similar documentation and information as would be required in a Registration Statement under the Securities Act.

 

Item 7.01 Regulation FD Disclosure.

 

On January 27, 2017, the Company issued a press release announcing the entry into and the closing of the transactions contemplated by the One Exam Exchange Agreement and related matters as described above in Item 2.01 . A copy of the press release is furnished as Exhibit 99.1 hereto.

 

The information responsive to Item 7.01 of this Form 8-K and Exhibit 99.1 attached hereto, shall not be deemed “ filed ” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“ Exchange Act ”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit      
Number Description of Exhibit   Filing
2.1+ Share Exchange Agreement by and among the Company, One Exam Prep LLC and the sole member of One Exam Prep LLC dated January 24, 2017   Filed herewith.
10.1 Non-Recourse Secured Convertible Promissory Note in the amount of $300,000, owed by the Company to Rob Estell, dated January 20, 2017   Filed herewith.
10.2 Security and Pledge Agreement by the Company in favor of Rob Estell, dated January 20, 2017   Filed herewith.
10.3 Consulting Agreement with Rob Estell, dated January 24, 2017   Filed herewith.
10.4 Form of Lock-Up Agreement   Incorporated by reference to Exhibit 10.6 to our Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 25, 2017
99.1 Press Release Dated January 27, 2017   Furnished herewith.

_______________

+ Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that Panther Biotechnology Inc. may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.

 

 

 

 

  3  
 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Panther Biotechnology Inc.
   
   
Date: January 30, 2017 By:  /s/ Evan M. Levine
 

Evan M. Levine,

Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  4  
 

 

EXHIBIT INDEX

 

Exhibit      
Number Description of Exhibit   Filing
2.1+ Share Exchange Agreement by and among the Company, One Exam Prep LLC and the sole member of One Exam Prep LLC dated January 24, 2017   Filed herewith.
10.1 Non-Recourse Secured Convertible Promissory Note in the amount of $300,000, owed by the Company to Rob Estell, dated January 20, 2017   Filed herewith.
10.2 Security and Pledge Agreement by the Company in favor of Rob Estell, dated January 20, 2017   Filed herewith.
10.3 Consulting Agreement with Rob Estell, dated January 24, 2017   Filed herewith.
10.4 Form of Lock-Up Agreement   Incorporated by reference to Exhibit 10.6 to our Current Report on Form 8-K, filed with the Securities and Exchange Commission on January 25, 2017
99.1 Press Release Dated January 27, 2017   Furnished herewith.

_______________

+ Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. A copy of any omitted schedule or exhibit will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that Panther Biotechnology Inc. may request confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.

 

 

 

 

 

 

 

 

 

 

 

 

  5  

Exhibit 2.1

 

SHARE EXCHANGE AGREEMENT

 

BY AND BETWEEN

 

PANTHER BIOTECHNOLOGY, INC.

 

A NEVADA CORPORATION

 

ONE EXAM PREP LLC

 

A FLORIDA LIMITED LIABILITY COMPANY

 

AND

 

THE MEMBERS OF ONE EXAM PREP LLC

 

DATED

 

JANUARY 24, 2017 AND

 

EFFECTIVE

 

JANUARY 1, 2017

 

 

 

 

 

 

 

 

     
 

 

TABLE OF CONTENTS

 

ARTICLE I. REPRESENTATIONS, COVENANTS, AND WARRANTIES OF OEP AND THE OEP MEMBERS 2
1.1.   Organization. 2
1.2.   Capitalization. 2
1.3.   Subsidiaries and Predecessor Corporations. 2
1.4.   Other Information. 2
1.5.   Options, Warrants, Convertible Securities. 3
1.6.   Absence of Certain Changes or Events. 3
1.7.   OEP and Related Matters. 4
1.8.   Litigation and Proceedings. 4
1.9.   Contracts. 4
1.10.   Material Contract Defaults. 5
1.11.   No Conflict With Other Instruments. 5
1.12.   Governmental Authorizations. 6
1.13.   Compliance With Laws and Regulations. 6
1.14.   Approval of Agreement. 6
1.15.   Material Transactions or Affiliations. 6
1.16.   The OEP Schedules. 6
1.17.   Valid Obligation. 7
1.18.   Acquisition of the Securities. 7
1.19.   Exemption from Registration. 8
1.20.   Representations, Acknowledgements and Warranties of the OEP Members. 8
1.21.   Intellectual Property. 10
1.22.   Compliance With Laws. 13
1.23.   Environmental Matters. 14
1.24.   Insurance Coverage. 14
1.25.   Customer, Supplier and Employee Relations. 15
1.26.   Product and Service Matters. 15
1.27.   Compliance with United States Foreign Corrupt Practices Act. 15
1.28.   Insider Trading. 16
1.29.   Closing Date Releases. 16
1.30.   No Other Representations or Warranties. 17
1.31.   No Untrue Representation or Warranty. 17
ARTICLE II. REPRESENTATIONS, COVENANTS, AND WARRANTIES OF THE COMPANY 17
2.1.   Organization. 17
2.1.   Trading Status. 18
2.2.   Capitalization. 18
2.3.   No Conflict or Violation; Default; Confirmations. 18
2.4.   Convertible Securities, Options or Warrants. 19
2.5.   Title and Related Matters. 19
2.6.   Litigation and Proceedings. 20

 

 

 

 

  i  
 

 

2.7.   Approval of Agreement. 20
2.8.   Valid Obligation. 20
2.9.   No Other Representations or Warranties. 20
2.10.   No Untrue Representation or Warranty. 21
ARTICLE III. PLAN OF EXCHANGE 21
3.1.   The Exchange. 21
3.2.   Closing. 21
3.3.   Tradability of Securities. 22
3.4.   Termination. 23
3.5.   Effect of Termination. 24
ARTICLE IV. SPECIAL COVENANTS 24
4.1.   Access to Properties and Records. 24
4.2.   Delivery of Books and Records and Bank Accounts. 25
4.3.   Third Party Consents and Certificates. 25
4.4.   Actions Prior to Closing. 25
4.5.   Post-Closing Conditions. 26
4.6.   Potential For Earn-Out Consideration. 26
ARTICLE V. CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY 27
5.1.   Ownership of OEP. 27
5.2.   Accuracy of Representations and Performance of Covenants. 27
5.3.   Officer’s Certificate. 28
5.4.   No Material Adverse Change. 28
5.5.   Approval by OEP. 28
5.6.   No Governmental Prohibition. 28
5.7.   Consents. 28
5.8.   Due Diligence. 28
5.9.   Employment and Related Agreements. 29
5.10.   Other Closing Conditions. 29
ARTICLE VI. CONDITIONS PRECEDENT TO OBLIGATIONS OF OEP AND THE OEP MEMBERS 29
6.1.   Accuracy of Representations and Performance of Covenants. 29
6.2.   Officer’s Certificate. 29
6.3.   No Material Adverse Change. 29
6.4.   No Governmental Prohibition. 30
6.5.   Consents. 30
6.6.   Other Closing Conditions. 30
ARTICLE VII. INDEMNIFICATION 30
7.1.   Indemnification by the OEP Members. 30
7.2.   Indemnification by the Company. 30
7.3.   Survival of Representations, Warranties and Covenants. 31
7.4.   Notice and Opportunity to Defend. 31

 

 

 

 

  ii  
 

 

7.5.   Remedies Exclusive. 32
7.6.   Emergency Relief. 32
7.7.   Right to Set Off. 32
ARTICLE VIII. CONFIDENTIALITY 32
8.1.   Confidentiality. 32
8.2.   Enforceability. 32
ARTICLE IX. DEFINITIONS 33
9.1.   Certain Definitions. 33
9.2.   Other Definitional Provisions. 36
ARTICLE X. MISCELLANEOUS 37
10.1.   No Bankruptcy and No Criminal Convictions. 37
10.2.   Broker/Finder’s Fee. 38
10.3.   Governing Law and Jurisdiction. 38
10.4.   Notices. 38
10.5.   Attorney’s Fees. 39
10.6.   Confidentiality. 39
10.7.   Publicity. 40
10.8.   Schedules and Exhibits. 40
10.9.   Schedules; Knowledge. 40
10.10.   Third Party Beneficiaries. 40
10.11.   Expenses. 41
10.12.   Entire Agreement. 41
10.13.   Survival; Termination. 41
10.14.   Counterparts. 41
10.15.   Amendment or Waiver. 41
10.16.   Best Efforts. 41
10.17.   Remedies. 41
10.18.   Severability. 42
10.19.   Independent Nature of Sellers’ Obligations and Rights. 42
10.20.   No Presumption from Drafting. 42
10.21.   Review and Construction of Documents. 42
10.22.   Headings; Gender. 43
10.23.   Transaction Expenses. 43
10.24.   Cooperation Following the Closing. 43
10.25.   Counterparts, Effect of Facsimile, Emailed and Photocopied Signatures. 43

 

 

 

 

 

 

 

  iii  
 

 

SHARE EXCHANGE AGREEMENT

 

THIS SHARE EXCHANGE AGREEMENT (this “ Agreement ”) is entered into as of this 24th day of January 2017, by and among Panther Biotechnology, Inc. , a Nevada corporation, having an address at 1517 San Jacinto Street, Houston, Texas 77002 (the “ Company ”) and One Exam Prep LLC , a Florida limited liability company, having an address at 4400 Sample Road, Coconut Creek, Florida 33073 (“ OEP ”), and the person(s) executing this Agreement listed on the signature page hereto under the heading “ OEP Members ” (referred to as the “ OEP Members ”), each a “ Party ” and collectively the “ Parties, ” upon the following premises:

 

PREMISES

 

WHEREAS , the OEP Members own all of the membership units (“ OEP Units ”), totaling one-hundred percent (100%) of the issued and outstanding membership units of OEP;

 

WHEREAS , the Company is a publicly held corporation organized under the laws of the State of Nevada, whose common stock trades on the OTC Pink Sheets Market under the symbol “ PBYA ”;

 

WHEREAS , OEP is a privately held limited liability company organized under the laws of the state of Florida;

 

WHEREAS , the Company desires to acquire 100% of the issued and outstanding securities of OEP in exchange for unissued shares of the Company’s common stock (the “ Exchange Offer ” or the “ Exchange ”), so that OEP will become a wholly-owned subsidiary of the Company;

 

WHEREAS , the Parties intend for the Exchange to be afforded tax free treatment under United States Internal Revenue Code; and

 

WHEREAS , the OEP Members desire to exchange all of their membership units of OEP in exchange for shares of authorized but unissued shares of common stock of the Company as set forth below.

 

CERTAIN CAPITALIZED TERMS USED HEREIN HAVE THE MEANINGS GIVEN TO SUCH TERMS IN ARTICLE IX .

 

AGREEMENT

 

NOW THEREFORE , on the stated premises and for and in consideration of the mutual covenants and agreements hereinafter set forth and the mutual benefits to the Parties to be derived herefrom, the receipt and sufficiency of which is hereby acknowledged, it is hereby agreed as follows:

 

 

 

 

  4  
 

 

ARTICLE I.
REPRESENTATIONS, COVENANTS, AND WARRANTIES OF OEP AND THE OEP MEMBERS

 

As an inducement to and to obtain the reliance of the Company, except as set forth on the OEP Schedules (as hereinafter defined, which shall contain any exceptions or qualifications to the representations and warranties are set forth below), OEP and the OEP Members represent and warrant as follows (which shall be re-confirmed at Closing):

 

1.1.             Organization . OEP is a limited liability company duly organized, validly existing, and in good standing under the laws of Florida. OEP has the corporate power and is duly authorized, qualified, franchised, and licensed under all applicable Laws, regulations, ordinances, and orders of public authorities to own all of its properties and assets and to carry on its business in all material respects as it is now being conducted, including qualifications to do business as a foreign corporation in the states or countries in which the character and location of the assets owned by it or the nature of the business transacted by it requires qualification, except where failure to be so qualified would not have a material adverse effect on its business. Included in the OEP Schedules are complete and correct copies of the Articles of Organization and Operating Agreement (or similar organizational documents) of OEP as in effect on the date hereof. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of OEP’s Articles of Organization (or similar organizational documents) or Operating Agreement. OEP has taken all actions required by Law, its Articles of Organization and Operating Agreement (or similar organizational documents), or otherwise to authorize the execution and delivery of this Agreement. OEP has full power, authority, and legal right and has taken all action required by Law, its Articles of Organization and Operating Agreement (or similar organizational documents), and otherwise to consummate the transactions herein contemplated.

 

1.2.             Capitalization.

 

1.2.1         All issued and outstanding membership units of OEP are legally issued, fully paid, and non-assessable and not issued in violation of the preemptive or other rights of any person.

 

1.3.             Subsidiaries and Predecessor Corporations . OEP does not have any predecessor corporation(s) or subsidiaries other than as set forth on Schedule 1.3 .

 

1.4.             Other Information.

 

1.4.1         OEP has no liabilities with respect to the payment of any federal, provincial, state, county, local or other Taxes (including any deficiencies, interest or penalties), except for Taxes accrued but not yet due and payable or as provided in the OEP Schedules.

 

 

 

 

  5  
 

 

1.4.2         OEP has filed all federal, provincial, state or local income and/or franchise Tax returns required to be filed by it from inception to the date hereof. Each of such income Tax returns reflects the Taxes due for the period covered thereby, except for amounts which, in the aggregate, are immaterial.

 

1.4.3         The books and records of OEP are in all material respects complete and correct and have been maintained in accordance with good business and accounting practices.

 

1.4.4         OEP has no material liabilities, direct or indirect, matured or unmatured, contingent or otherwise in excess of Five Thousand Dollars ($5,000) except as disclosed in writing to the Company on Schedule 1.4.4 , which liabilities in aggregate shall not exceed $15,000, including payables, on the Closing Date, but exclusive of professional fees and expenses related to the transactions contemplated herein.

 

1.5.             Options, Warrants, Convertible Securities. Other than as set forth on Schedule 1.5 , there are no outstanding subscriptions, options, calls, contracts, commitments, understandings, restrictions, arrangements, rights or warrants, including any right of conversion or exchange under any outstanding security, instrument or other agreement and also including any rights plan or other antitakeover agreement, obligating OEP to issue, deliver or sell, or cause to be issued, delivered or sold, additional shares of the capital stock of OEP or obligating OEP to grant, extend or enter into any such agreement or commitment and there are no outstanding stock appreciation rights or similar derivative securities or rights of OEP.

 

1.6.             Absence of Certain Changes or Events . Except as set forth in this Agreement or the OEP Schedules, since January 1, 2016:

 

1.6.1         There has not been (i) any material adverse change in the proposed business, operations, properties, assets, or condition of OEP or (ii) any damage, destruction, or loss to OEP (whether or not covered by insurance) materially and adversely affecting the business or financial condition of OEP;

 

1.6.2         OEP has not (i) amended its Articles of Organization or Operating Agreement (or similar documents;); (ii) declared or made, or agreed to declare or make, any payment of dividends or distributions of any assets of any kind whatsoever to stockholders or purchased or redeemed, or agreed to purchase or redeem, any of its capital stock; (iii) waived any rights of value which in the aggregate are outside of the ordinary course of business or material considering the business of OEP; (iv) made any material change in its method of management, operation or accounting; (v) entered into any other material transaction other than sales in the ordinary course of its business; (vi) made any accrual or arrangement for payment of bonuses or special compensation of any kind or any severance or termination pay to any present or former officer or employee; (vii) increased the rate of compensation payable or to become payable by it to any of its officers or directors or any of its salaried employees whose monthly compensation exceeds Five Thousand Dollars ($5,000); or (viii) made any increase in any profit sharing, bonus, deferred compensation, insurance, pension, retirement, or other employee benefit plan, payment, or arrangement made to, for, or with its officers, directors, or employees;

 

 

 

 

 

  6  
 

 

1.6.3         OEP has not (i) borrowed or agreed to borrow any funds or incurred, or become subject to, any material obligation or liability (absolute or contingent) in excess of $5,000 except as disclosed herein and except liabilities incurred in the ordinary course of business; (ii) paid or agreed to pay any material obligations or liability (absolute or contingent) other than current liabilities, and current liabilities incurred in the ordinary course of business and professional and other fees and expenses in connection with the preparation of this Agreement and the consummation of the transactions contemplated hereby; (iii) sold or transferred, or agreed to sell or transfer, any of its assets, properties, or rights (except assets, properties, or rights not used or useful in its business which, in the aggregate have a value of less than Five Thousand Dollars ($5,000), or canceled, or agreed to cancel, any debts or claims (except debts or claims which in the aggregate are of a value of less than Five Thousand Dollars ($5,000); or (iv) made or permitted any amendment or termination of any contract, agreement, or license to which they are a party if such amendment or termination is material, considering the business of OEP, other than in the ordinary course of business; and

 

1.6.4         To the best Knowledge of the OEP Members, OEP has not become subject to any Law or regulation which materially and adversely affects, or in the future may adversely affect, the business, operations, properties, assets, or condition of OEP.

 

1.7.             OEP and Related Matters. No third party has any right to, and OEP has not received any notice of infringement of or conflict with asserted rights of others with respect to, any product, technology, data, trade secrets, know-how, proprietary techniques, trademarks, service marks, trade names, or copyrights which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a materially adverse effect on the proposed business, operations, financial condition, income, or business prospects of OEP or any material portion of its properties, assets, or rights.

 

1.8.             Litigation and Proceedings . Other than as set forth on Schedule 1.8 , there are no actions, suits, or proceedings pending or, to the Knowledge of the OEP Members after reasonable investigation, threatened by or against OEP or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind. The OEP Members do not have any Knowledge of any material default with respect to any judgment, order, injunction, decree, award, rule, or regulation of any court, arbitrator, or governmental agency or instrumentality or of any circumstances which, after reasonable investigation, would result in the discovery of such a default.

 

1.9.             Contracts.

 

1.9.1         Except as disclosed on Schedule 1.9.1 , there are no material contracts, agreements, franchises, license agreements, debt instruments or other commitments to which OEP is a party or by which any of its assets, products, technology, or properties are bound other than those incurred in the ordinary course of business (as used in this Agreement, a “ material ” contract, agreement, franchise, license agreement, debt instrument or commitment is one which (i) will remain in effect for more than six (6) months after the date of this Agreement and (ii) involves obligations of at least Ten Thousand Dollars ($10,000) unless otherwise disclosed pursuant to this Agreement);

 

 

 

 

 

  7  
 

 

1.9.2         All contracts, agreements, franchises, license agreements, and other commitments, if any, to which OEP is a party and which are material to the operations or proposed operations of OEP taken as a whole are valid and enforceable by OEP in all material respects, except as limited by bankruptcy and insolvency laws and by other laws affecting the rights of creditors generally;

 

1.9.3         OEP is not a party to or bound by, and the properties of OEP are not subject to, any contract, agreement, other commitment or instrument; any charter or other corporate restriction; or any judgment, order, writ, injunction, decree, or award which materially and adversely affects, the business operations, properties, assets, or condition of OEP; and

 

1.9.4         Except as included or described in the OEP Schedules, OEP is not a party to any oral or written (i) contract for the employment of any officer or employee which is not terminable on thirty (30) days, or less notice; (ii) profit sharing, bonus, deferred compensation, stock option, severance pay, pension benefit or retirement plan; (iii) agreement, contract, or indenture relating to the borrowing of money; (iv) guaranty of any obligation, other than one on which OEP is a primary obligor, for the borrowing of money or otherwise, excluding endorsements made for collection and other guaranties of obligations which, in the aggregate do not exceed more than one (1) year or providing for payments in excess of Five Thousand Dollars ($5,000) in the aggregate; (v) collective bargaining agreement; or (vi) agreement with any present or former officer or director of OEP.

 

1.10.         Material Contract Defaults . OEP is not in default in any material respect under the terms of any outstanding material contract, agreement, lease, or other commitment which is material to the business, operations, properties, assets or condition of OEP, and there is no event of default in any material respect under any such contract, agreement, lease, or other commitment in respect of which OEP has not taken adequate steps to prevent such a default from occurring.

 

1.11.         No Conflict With Other Instruments . The execution of this Agreement and the consummation of the transactions contemplated by this Agreement will not result in the breach of any term or provision of, constitute an event of default under, or terminate, accelerate or modify the terms of any material indenture, mortgage, deed of trust, or other material contract, agreement, or instrument to which OEP is a party or to which any of its properties or operations are subject as of the date of this Agreement and/or as of the Closing Date.

 

 

 

 

 

 

  8  
 

 

1.12.         Governmental Authorizations . Except as set forth in the OEP Schedules, OEP has all licenses, franchises, permits, and other governmental authorizations that are legally required to enable it to conduct its business in all material respects as conducted on the date hereof. Except for compliance with federal, provincial and state securities and corporation laws, as hereinafter provided, no authorization, approval, consent, or order of, or registration, declaration, or filing with, any court or other Governmental Body is required in connection with the execution and delivery by OEP and the OEP Members of this Agreement and the consummation by OEP and the OEP Members of the transactions contemplated hereby.

 

1.13.         Compliance With Laws and Regulations . Except as set forth in the OEP Schedules, to the best Knowledge of the OEP Members, OEP has complied with all applicable statutes and regulations of any federal, provincial, state, or other governmental entity or agency thereof, except to the extent that noncompliance would not materially and adversely affect the business, operations, properties, assets, or condition of OEP or except to the extent that noncompliance would not result in the occurrence of any material liability for OEP.

 

1.14.         Approval of Agreement . The Board of Managers of OEP shall have authorized the execution and delivery of this Agreement by OEP and approved this Agreement and the transactions contemplated hereby.

 

1.15.         Material Transactions or Affiliations . Set forth in the OEP Schedules is a description, if applicable, of every contract, agreement, or arrangement between OEP and any predecessor and any person who was at the time of such contract, agreement, or arrangement an officer, director, or person owning of record, or known by any OEP Member to own beneficially, five percent (5%) or more of the issued and outstanding securities of OEP and which is to be performed in whole or in part after the date hereof or which was entered into not more than three (3) years prior to the date hereof. Except as disclosed in the OEP Schedules or otherwise disclosed herein, no officer, director, or five percent (5%) member of OEP has, or has had since formation, any known interest, direct or indirect, in any transaction with OEP which was material to the business of OEP. There are no commitments by OEP, whether written or oral, to lend any funds, or to borrow any money from, or enter into any other transaction with, any such affiliated person.

 

1.16.         The OEP Schedules . OEP will deliver to the Company the following schedules, if such schedules are applicable to the business of OEP, which are collectively referred to as the “ The OEP Schedules ” and which consist of separate schedules dated as of the date of execution of this Agreement, all certified by the principal executive officer of OEP as complete, true, and correct as of the date of this Agreement in all material respects, which schedules shall be delivered within 10 days following the execution of this Agreement:

 

 

 

 

 

  9  
 

 

1.16.1     a schedule containing complete and correct copies of the Articles of Organization and Operating Agreement or similar organizational documents of OEP in effect as of the date of this Agreement;

 

1.16.2     a schedule containing any Resolutions of the Managers and Members of OEP since formation;

 

1.16.3     a schedule containing Minutes of meetings of the Managers and Members of OEP since formation;

 

1.16.4     a schedule containing a list indicating the name and address of each member of OEP together with the number of units owned by him, her or it;

 

1.16.5     a schedule listing any and all federal, provincial, state and local Tax identification numbers of OEP and containing complete and correct copies of all federal, provincial, state and local Tax returns filed by OEP;

 

1.16.6     a schedule setting forth any other information, together with any required copies of documents, required to be disclosed by OEP. Any fact known to be, or to the best Knowledge of the OEP Members or after reasonable investigation, reasonably believed to be, contrary to any of the representations, covenants, and warranties made in ARTICLE I are required to be disclosed in the OEP Schedules pursuant to this Section 1.16 ; and

 

1.16.7     a schedule of any and all limitations or qualifications or exceptions to the representations, covenants and warranties of OEP and OEP Members contained in ARTICLE I of this Agreement, if any.

 

OEP shall cause the OEP Schedules and the instruments and data delivered to the Company hereunder to be promptly updated after the date hereof up to and including the Closing Date.

 

1.17.         Valid Obligation . This Agreement and all agreements and other documents executed by OEP and OEP Members in connection herewith constitute the valid and binding obligation of OEP and OEP Members, enforceable in accordance with its or their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding therefor may be brought.

 

1.18.         Acquisition of the Securities . The OEP Members are acquiring the Securities (as defined in ARTICLE III ) for their own account without the participation of any other person and with the intent of holding the Securities for investment and without the intent of participating, directly or indirectly, in a distribution of the Securities, or any portion thereof, and not with a view to, or for resale in connection with, any distribution of the Securities, or any portion thereof. The OEP Members have read, understood and consulted with their legal counsel regarding the limitations and requirements of Section 5 of the Securities Act. The OEP Members will offer, sell, pledge, convey or otherwise transfer the Securities, or any portion thereof, only if: (i) pursuant to an effective registration statement under the Securities Act and any and all applicable state securities or Blue Sky laws or in a transaction which is otherwise in compliance with the Securities Act and such laws; or (ii) pursuant to a valid exemption from registration.

 

 

 

 

  10  
 

 

1.19.         Exemption from Registration . The Exchange and the transactions contemplated thereby, meet an exemption from registration pursuant to Section 4(a)(2) of the Securities Act, Rule 506 of Regulation D promulgated under the Securities Act and/or Regulation S of the Securities Act.

 

1.20.         Representations, Acknowledgements and Warranties of the OEP Members . The OEP Members (each a “ Share Recipient ”), represent, acknowledge and warrant the following to the Company, except as set forth on the OEP Schedules (as hereinafter defined, which shall contain any exceptions or qualifications to the representations and warranties are set forth below), and agree that such representations, acknowledgements and warranties shall be automatically reconfirmed on the Closing Date:

 

1.20.1     Each Share Recipient recognizes that the Securities have not been registered under the Securities Act, nor under the securities laws of any state and, therefore, cannot be resold unless the resale of the Securities is registered under the Securities Act or unless an exemption from registration is available. Each Share Recipient may not sell the Securities without registering them under the Securities Act and any applicable state securities laws unless exemptions from such registration requirements are available with respect to any such sale;

 

1.20.2     Each Share Recipient is acquiring the Securities for its own account for long-term investment and not with a view toward resale, fractionalization or division, or distribution thereof, and it does not presently have any reason to anticipate any change in its circumstances, financial or otherwise, or particular occasion or event which would necessitate or require the sale or distribution of the Securities. No one other than the Share Recipient will have any beneficial interest in said securities. Each Share Recipient agrees to set forth the terms of its ownership, record address and tax id number if applicable on the Form of Stock Registration Form, attached hereto as Exhibit A ;

 

1.20.3     Each Share Recipient acknowledges that it:

 

(i)                  is a “ sophisticated investor ” and an accredited investor as such term is defined in Rule 501 of Regulation D of the Securities Act of 1933, as amended, and

 

 

 

 

 

 

  11  
 

 

(ii)               is aware of, has received and had an opportunity to review (A) the (i) Company’s Annual Report on Form 10-K for the year ended May 31, 2016; and (ii) the Company’s Quarterly Reports on Form 10-Q and current reports on Form 8-K (which filings can be accessed by going to https://www.sec.gov/search/search.htm, typing “ Panther Biotechnology ” in the “ Company name ” field, and clicking the “ Search ” button), from May 31, 2016, to the date of such Share Recipient’s entry into this Agreement, in each case (i) through (ii), including the audited and unaudited financial statements, description of business, risk factors, results of operations, certain transactions and related business disclosures described therein (collectively the “ Disclosure Documents ”) and an independent investigation made by it of the Company; (B) has, prior to the date of this Agreement, been given an opportunity to review material contracts and documents of the Company and has had an opportunity to ask questions of and receive answers from the Company’s officers and Directors and has no pending questions as of the date of this Agreement; and (C) is not relying on any oral representation of the Company or any other person, nor any written representation or assurance from the Company; in connection with each Share Recipient’s acceptance of the Securities and investment decision in connection therewith. Each Share Recipient acknowledges that due to its receipt of and review of the information described above, it has received similar information as would be included in a Registration Statement filed under the Securities Act;

 

1.20.4     Each Share Recipient has such knowledge and experience in financial and business matters such that the Share Recipient is capable of evaluating the merits and risks of an investment in the Securities and of making an informed investment decision, and does not require a representative in evaluating the merits and risks of an investment in the Securities;

 

1.20.5     Each Share Recipient has had an opportunity to ask questions of and receive satisfactory answers from the Company, or any person or persons acting on behalf of the Company, concerning the terms and conditions of the Exchange and the Company, and all such questions have been answered to the full satisfaction of such Share Recipient;

 

1.20.6     Each Share Recipient recognizes that an investment in the Company is a speculative venture and that the total amount of consideration tendered in connection with the Exchange Offer is placed at the risk of the business and may be completely lost. The ownership of the Securities as an investment involves special risks;

 

1.20.7     Each Share Recipient realizes that the Securities cannot readily be sold as they will be restricted securities and therefore the Securities must not be accepted in the Exchange Offer unless such Share Recipient has liquid assets sufficient to assure that such purchase will cause no undue financial difficulties and such Share Recipient can provide for current needs and possible personal contingencies;

 

1.20.8     Each Share Recipient confirms and represents that it is able (i) to bear the economic risk of its investment, (ii) to hold the Securities for an indefinite period of time, and (iii) to afford a complete loss of its investment. Each Share Recipient also represents that it has (i) adequate means of providing for its current needs and possible personal contingencies, and (ii) has no need for liquidity in this particular investment;

 

 

 

 

 

 

  12  
 

 

1.20.9     All information which each Share Recipient has provided to the Company concerning such Share Recipient’s financial position and knowledge of financial and business matters is correct and complete as of the date hereof, and if there should be any material change in such information prior to the Closing Date, such Share Recipient will immediately provide the Company with such information;

 

1.20.10    Each Share Recipient has carefully considered and has, to the extent it believes such discussion necessary, discussed with its professional, legal, tax and financial advisors, the suitability of an investment in the Securities for its particular tax and financial situation and its advisers, if such advisors were deemed necessary, have determined that the Securities are a suitable investment for him, her, or it;

 

1.20.11 Each Share Recipient has not become aware of and has not been offered the Securities by any form of general solicitation or advertising, including, but not limited to, advertisements, articles, notices or other communications published in any newspaper, magazine, or other similar media or television or radio broadcast or any seminar or meeting where, to such Share Recipient’s Knowledge, those individuals that have attended have been invited by any such or similar means of general solicitation or advertising;

 

1.20.12    Each Share Recipient confirms and acknowledges that the Company is under no obligation to register or seek an exemption under any federal and/or state securities acts for any sale or transfer of the Securities by Share Recipients, and each Share Recipient is solely responsible for determining the status, in his, her or its hands, of the Securities acquired in connection herewith and the availability, if required, of exemptions from registration for purposes of sale or transfer of the Securities;

 

1.20.13    Each Share Recipient confirms and acknowledges that no federal or state agency has made any finding or determination as to the fairness of the Securities for investment or any recommendation or endorsement of the Securities. The Securities have not been registered under the Securities Act or the securities laws of any State and are being offered and sold in reliance on exemptions from the registration requirements of the Securities Act and such state laws; and

 

1.20.14    Each Share Recipient agrees and confirms that such Share Recipient may have Section 16 and Schedule 13D filing obligations with the SEC immediately upon the consummation of the transactions contemplated herein and such Share Recipient agrees to take whatever action necessary to make and file such required filings with the SEC.

 

1.21.         Intellectual Property.

 

1.21.1     OEP owns all right, title and interest in the intellectual property assets set forth in Schedule 1.21.3 , Schedule 1.21.4 and Schedule 1.21.7 and such ownership is free and clear of all Liens and Encumbrances, obligatory payments to others and the obligation to grant rights to others. Except as set forth on Schedule 1.21.1 , OEP owns all right, title and interest in, or possesses adequate licenses or other valid rights to use (without the making of any payment to others or the obligation to grant rights to others in exchange), free and clear of all Liens and Encumbrances, all other Intellectual Property owned by OEP or used in connection with the operation of its business as currently conducted, including without limitation the intellectual property set forth on Schedule 1.21.3 , Schedule 1.21.4 and Schedule 1.21.7 . OEP has taken all necessary and desirable action to maintain each item of Intellectual Property that OEP owns or uses with respect to its business. All maintenance fees of patents set forth in Schedule 1.21.3 which become due (without the payment of a surcharge) prior to the Closing shall be paid by OEP prior to the Closing.

 

 

 

 

  13  
 

 

1.21.2     OEP has not interfered with, infringed upon, misappropriated or otherwise come into conflict with any Intellectual Property rights of any other Person, and none of the directors and officers (and employees with responsibility for Intellectual Property matters) of OEP has ever received any charge, complaint, claim, demand or notice from any Governmental Body or other Person alleging any such interference, infringement, misappropriation or conflict (including any claim that OEP must license or refrain from using any Intellectual Property rights of any other Person). To OEP’s Knowledge, no Person has interfered with, infringed upon, misappropriated or otherwise come into conflict with any Intellectual Property rights of OEP.

 

1.21.3     Schedule 1.21.3 identifies (i) each patent or patent registration which has been issued to OEP in the United States and all jurisdictions worldwide with respect to any item of Intellectual Property, and (ii) each patent application or application for patent registration which OEP has filed with respect to any item of Intellectual Property anywhere in the world (together with any exceptions). OEP has delivered to the Company correct and complete copies of all such patents, registrations and applications (as amended to date) and has made available to the Company correct and complete copies of all other written documentation evidencing prosecution (if applicable) of each such item of Intellectual Property (the “ Patents ”). Prior to Closing, OEP shall deliver to designated counsel of the Company all files in the possession of OEP and its attorneys relating to the prosecution and maintenance of assets set forth in Schedule 1.21.3 (the “ Patent Documentation ”).

 

1.21.4     Schedule 1.21.4 identifies each registered and unregistered trademark, including product names and domain names, used by OEP in connection with its business. OEP has delivered to the Company correct and complete copies of all written documentation evidencing ownership and use of each such product name and domain name as set forth on Schedule 1.21.4 . OEP represents that it owns no trademark registrations or applications for registration in any jurisdiction and no such applications have been filed by OEP, any Affiliate thereof or its predecessor-in-interest.

 

 

 

 

 

 

 

 

 

 

 

 

 

  14  
 

 

1.21.5     OEP represents that it owns no copyright registrations or applications in any jurisdiction and no such applications have been filed by OEP, any Affiliate thereof or its predecessor-in-interest.

  

1.21.6     OEP represents that neither itself, any Affiliate thereof nor its predecessor-in-interest is a party to any license, agreement or other permission which OEP has granted to any other Person with respect to any item of Intellectual Property in the United States and any jurisdictions worldwide and that no such licenses, agreements or other permissions exist.

 

1.21.7     Schedule 1.21.7 identifies trade secrets and confidential business information of OEP.

 

1.21.8     With respect to each item of Intellectual Property required to be identified on Schedule 1.21.3 , Schedule 1.21.4 and Schedule 1.21.7 :

 

(i)                  except as set forth on Schedule 1.21.1 , OEP owns all right, title and interest in and to such item, free and clear of any Liens and Encumbrances;

 

(ii)               except as set forth in Schedule 1.21.1 , OEP is unaware of any transfers of ownership or title of Intellectual Property;

 

(iii)             such item is not subject to any outstanding injunction, judgment, order, decree, ruling or charge;

 

(iv)              no action, suit, proceeding, hearing, investigation, charge, complaint, claim, or demand is pending or, to OEP’s or any OEP Member’s Knowledge, threatened which challenges the legality, validity, enforceability, use or ownership of such item;

 

(v)                no prior art or activity is known by OEP which would affect the validity or enforceability of the claimed subject matter set forth in Schedule 1.21.3 , or the validity or enforceability of the trademarks set forth in Schedule 1.21.4 ;

 

(vi)              OEP has not agreed to indemnify any Person for or against any interference, infringement, misappropriation or other conflict with respect to such item;

 

(vii)           all licenses, agreements and other permissions pertaining to such item and all other rights to which OEP is entitled with respect thereto are in compliance in all respects with all applicable Laws in all jurisdictions worldwide, including those pertaining to remittance of foreign exchange and Taxes; and

 

 

 

 

 

 

 

 

  15  
 

 

(viii)         OEP has not made a previous assignment, sale, transfer or agreement constituting a present or future assignment, sale or transfer of, or granted any Lien on such item; nor has OEP granted any release, covenant not to sue or other non-assertion assurance to any Person with respect to such item which could reasonably be expected to have an adverse effect on the aggregate value of the Intellectual Property.

 

1.21.9     OEP represents that it does not use any computer software or Intellectual Property owned by any Person other than OEP pursuant to any license, sublicense, agreement or permission and that no such licenses, sublicenses, agreements or permissions exist.

 

1.21.10    To OEP’s Knowledge, the continued operation of its business as currently conducted do not and will not interfere with, infringe upon, misappropriate or otherwise come into conflict with, any Intellectual Property rights of any Person.

 

1.21.11    OEP has no Knowledge of any new products, inventions, procedures, or methods of manufacturing or processing that any competitors or other Persons have developed which reasonably could be expected to supersede or make obsolete any product or process of OEP.

 

1.22.         Compliance With Laws .

 

1.22.1     OEP is not in violation of any laws, governmental orders, rules or regulations, whether federal, state or local Laws, to which it or any of its assets or properties are subject, which may have a material adverse effect on its business or operations. Except as set forth in Schedule 1.22.1 , OEP has not received notice of any violation of any Law, or any potential liability under any Law, relating to the operation of OEP or its business or operations, OEP is not aware of any such violation or potential liability.

 

1.22.2     Schedule 1.22.2 sets forth a list of each government or regulatory license, authorization, permit, franchise, consent and approval (the “ Permits ”) issued and held by or on behalf of OEP or, required to be so issued and held in connection with its business or operations as currently conducted by OEP. Except as disclosed in Schedule 1.22.2 , OEP is the authorized legal holder of the Permits, and each Permit is valid and in full force and effect. OEP is not in default under, and no condition exists that with notice or lapse of time or both could constitute a default or could give rise to a right of termination, cancellation or acceleration under, any Permit held by OEP.

 

1.22.3     No officer, director or greater than 20% member of OEP is considered a ‘bad actor’ under, or subject to disqualification under, Rule 506(d) of the Securities Act or has been subject to any event which would require disclosure by OEP under Rule 506(e) of the Securities Act in any offering under Regulation D.

 

 

 

 

  16  
 

 

1.23.         Environmental Matters .

 

1.23.1     The operations of OEP are currently and have been in compliance in all material respects with all applicable Environmental Laws and all licenses and permits issued pursuant to Environmental Laws or otherwise (“ Environmental Permits ”);

 

1.23.2     OEP has obtained and currently maintains all Environmental Permits required under all applicable Environmental Laws necessary to operate;

 

1.23.3     OEP is not the subject of any outstanding written order or contract with any Governmental Body or other Person respecting any Environmental Laws or any Release or threatened Release of a hazardous material. “ Release ” means any actual or threatened release, spill, emission, leaking, pumping, injection, deposit, disposal, discharge, dispersal, migration or leaching into the indoor or outdoor environment, or into or out of any property;

 

1.23.4     OEP has not received any written communication alleging either that it may be in violation of any Environmental Law or Environmental Permit or that it may have any liability under any Environmental Law;

 

1.23.5     OEP has not incurred, assumed or undertaken any contingent liability in connection with any Release of any hazardous materials into the indoor or outdoor environment (whether on-site or off-site) and there are no facts, circumstances or conditions relating to, arising out of or attributable to it that could give rise to material liability under Environmental Laws;

 

1.23.6     To the Knowledge of OEP and the OEP Members, there is not located at any of the properties of OEP any (i) underground storage tanks, (ii) asbestos or asbestos-containing material, (iii) equipment containing polychlorinated biphenyls, (iv) lead-based paint, or (v) mold; and

 

1.23.7     OEP has provided to the Company all environmentally related audits, studies, reports, analyses, and results of investigations that have been performed within the previous five years with respect to the currently or previously owned, leased or operated properties of OEP.

 

1.24.         Insurance Coverage . Schedule 1.24 contains a list of all of the insurance policies and fidelity bonds covering the assets, businesses, operations, employees, officers and agents of OEP. There is no material claim by OEP pending under any of such policies or bonds as to which coverage has been questioned, denied or disputed by the underwriters of such policies or bonds. All premiums due and payable under all of such policies and bonds have been paid, and OEP has complied in all material respects with the terms and conditions of all of such policies and bonds. Such policies of insurance and bonds are in full force and effect. Neither OEP nor any of the OEP Members have Knowledge of any threatened termination of, or premium increase with respect to, any of such policies or bonds.

 

1.25.         Customer, Supplier and Employee Relations . Schedule 1.25 includes a complete and correct list of (a) all customers of OEP who have made aggregate purchases in excess of 5% of the total revenues of OEP in calendar year 2016, and (b) all suppliers from whom OEP has purchased in excess of $10,000 in equipment or supplies in calendar year 2016. The relationships of OEP with such customers and suppliers and the employees of OEP are good commercial working relationships and, except as disclosed in Schedule 1.25 , none of such customers, suppliers or employees has canceled, terminated or otherwise materially altered or notified OEP of any intention to cancel, terminate or materially alter its relationship with OEP since December 31, 2015 and there will not be any such change as a result of the transactions contemplated by this Agreement.

 

1.26.         Product and Service Matters . Except as disclosed in Schedule 1.26 , each product manufactured, sold, leased, delivered or installed or services performed by OEP prior to the Closing has, in all respects, complied with and conformed to all applicable federal, state, local or foreign laws and regulations, contractual commitments and all applicable warranties of OEP. Schedule 1.26 includes copies of the standard terms and conditions of sale, lease, delivery or installation for the products and services of OEP (containing applicable guaranty, warranty, and indemnity provisions). Except as disclosed in Schedule 1.26 , none of such products or services is subject to any guaranty, warranty, or other indemnity beyond the applicable standard terms and conditions of sale or lease.

 

1.27.         Compliance with United States Foreign Corrupt Practices Act .

 

(a)       OEP is in compliance with and has not made any payments that would be in violation of the United States Foreign Corrupt Practices Act (15 U.S.C. §§ 78dd-1, et seq.) (“ FCPA ”).

 

(b)       In connection with its compliance with the FCPA, there are no adverse or negative past performance evaluations or ratings by the U.S. Government, or any voluntary disclosures under the FCPA, any enforcement actions and, to the Knowledge of any OEP Member, there are no threats of enforcement actions, or any facts that could result in any adverse or negative performance evaluation related to the FCPA for OEP.

 

(c)       Neither the U.S. Government nor any other Person has notified OEP of any actual or alleged violation or breach of the FCPA.

 

(d)       OEP has not undergone and is not undergoing any audit, review, inspection, investigation, survey or examination of records relating to OEP’s compliance with the FCPA and, to the Knowledge of each OEP Member, there is no basis for any such audit, review, inspection, investigation, survey or examination of records.

 

 

 

 

 

 

  17  
 

 

(e)       OEP has not been and is not now under any administrative, civil or criminal investigation or indictment involving alleged false statements, false claims or other improprieties relating to OEP’s compliance with the FCPA and, to the Knowledge of each OEP Member, there is no basis for any such investigation or indictment.

 

(f)       OEP has not been and is not now a party to any administrative or civil litigation involving alleged false statements, false claims or other improprieties relating to OEP’s compliance with the FCPA and, to the Knowledge of each OEP Member, there is no basis for any such proceeding.

 

1.28.         Insider Trading . Each OEP Member certifies and confirms that it has not personally, nor through any third parties, purchased, nor caused to be purchased in the public marketplace any publicly-traded shares of the Company. Each OEP Member further certifies and confirms that it has not communicated the nature of the transactions contemplated herein, is not aware of any disclosure of non-public information regarding the Company or the transactions contemplated herein, and is not a party to any insider trading in the Company’s securities. Each OEP Member further certifies and confirms that it has not “ tipped ” any related parties nor third parties regarding the transactions contemplated herein, and/or advised any parties to purchase, sell or otherwise trade shares of the Company’s securities in the marketplace.

 

1.29.         Closing Date Releases .

 

1.29.1          Effective on the Closing Date, the OEP Members for themselves and their successors and assigns, hereby release, acquit and forever discharge OEP and its respective Affiliates, officers, directors, employees and agents and its respective successors and assigns of and from any and all Claims, demands, liabilities, responsibilities, disputes, causes of action and obligations of every nature whatsoever, liquidated or unliquidated, known or unknown, matured or unmatured, fixed or contingent, that the OEP Members have, own or hold as of the Closing Date, or have at any time previously had, owned or held against such parties, including, without limitation, all Liabilities created as a result of the, gross negligence and willful acts of OEP or the negligence of any of OEP or its employees and agents, or under a theory of strict liability, existing as of the Closing Date;  provided however , that such release shall not cover (a) any Claims against OEP or any of its Affiliates (other than OEP) unrelated in any way to OEP; (b) any Claims arising under any agreement between such OEP Member and OEP, previously disclosed to the Company, to be continued after the Closing Date; or (c) any Claims arising under this Agreement. Notwithstanding the foregoing, the releases and other agreements set forth in this  Section 1.29  shall not apply to or otherwise limit, restrict or affect the indemnification, exculpation and other obligations set forth in ARTICLE VII  or in any other document or agreement.

 

 

 

 

 

 

  18  
 

 

1.29.2          As of the date of this Agreement, each of the OEP Members hereby represent and warrant that such OEP Member has not previously assigned or transferred, or purported to assign or transfer, to any Person or entity whatsoever all or any part of the Claims, demands, liabilities, responsibilities, disputes, causes of action or obligations released in Section 1.29.1 . Each of the OEP Members represents and warrants that such OEP Member has read and understands all of the provisions of this  Section 1.29.1  and that the Member has been represented by legal counsel of the Members’ own choosing in connection with the negotiation, execution and delivery of this Agreement.

 

1.29.3          The release provided by the OEP Members pursuant to  Section 1.29.1  shall apply notwithstanding that the matter for which release is provided may relate to the ordinary, sole or contributory negligence, gross negligence, willful misconduct or violation of Law by a released party, including OEP and its Affiliates, officers, directors, employees and agents, and for liabilities based on theories of strict liability, and shall be applicable whether or not negligence of the released party is alleged or proven, it being the intention of the Parties to release the released party from and against its ordinary, sole and contributory negligence and gross negligence as well as liabilities based on the willful actions or omissions of the released party and Liabilities based on theories of strict liability.

 

1.30.         No Other Representations or Warranties . Except for the representations and warranties contained in this ARTICLE I or in any OEP Schedule, neither OEP, any OEP Member nor any other Person makes any other express or implied representation or warranty on behalf of OEP, the OEP Members, or any of their Affiliates or representatives to the Company.

 

1.31.         No Untrue Representation or Warranty . No representation or warranty contained in this Agreement or any attachment, schedule, exhibit, certificate or instrument furnished to the Company by OEP or the OEP Members pursuant hereto, or in connection with the transactions contemplated hereby, contains any untrue statement of a material fact, or omits to state any material fact necessary to make the statements contained herein or therein not misleading.

 

ARTICLE II.
REPRESENTATIONS, COVENANTS, AND WARRANTIES OF THE COMPANY

 

As an inducement to, and to obtain the reliance of the OEP Members, except as set forth in the Company Schedules (as hereinafter defined), the Company represents and warrants as follows (which shall be re-confirmed at Closing):

 

2.1.             Organization . The Company is a corporation duly organized, validly existing, and in good standing under the laws of Nevada and has the corporate power and is duly authorized, qualified, franchised, and licensed under all applicable laws, regulations, ordinances, and orders of public authorities to own all of its properties and assets, to carry on its business in all material respects as it is now being conducted and as contemplated after the Exchange, and except where failure to be so qualified would not have a material adverse effect on its business, there is no jurisdiction in which it is not qualified in which the character and location of the assets owned by it or the nature of the business transacted by it requires qualification. Included in the Company Schedules are complete and correct copies of the Articles of Incorporation and Bylaws (or similar organizational documents) of the Company as in effect on the date hereof. The execution and delivery of this Agreement does not, and the consummation of the transactions contemplated hereby will not, violate any provision of the Company’s Articles of Incorporation and Bylaws (or similar organizational documents). The Company has taken all action required by law, its Articles of Incorporation, its Bylaws (or similar organizational documents), or otherwise to authorize the execution and delivery of this Agreement, and the Company has full power, authority, and legal right and has taken all action required by Law, its Articles of Incorporation, its Bylaws, (or similar organizational documents) or otherwise to consummate the transactions herein contemplated.

 

 

 

 

  19  
 

 

2.1.             Trading Status . The Company’s common stock trades on the OTC Pink Sheets Market under the symbol “ PBYA ”. The Company has no Knowledge of any notices of non-compliance with the OTC Pink Sheets Market listing criteria.

 

2.2.             Capitalization . The Company is authorized to issue 100,000,000 shares of common stock and 10,000,000 shares of preferred stock. All issued and outstanding shares are legally issued, fully paid, and non-assessable and not issued in violation of the preemptive or other rights of any person.

 

2.3.             No Conflict or Violation; Default; Confirmations .

 

2.3.1         Neither the execution and delivery of this Agreement nor the consummation of the transactions contemplated hereby will violate, conflict with or result in a breach of or constitute a default under (a) or result in the termination or the acceleration of, or the creation in any Person of any right (whether or not with notice or lapse of time or both) to declare a default, accelerate, terminate, modify or cancel any indenture, contract, lease, sublease, license, mortgage, indenture, lease, loan agreement, note or other obligation or liability (each, a “ Company Contract ”) to which the Company is a party or by which it is bound, (b) any provision of the certificate of incorporation or Bylaws of the Company, (c) any judgment, order, decree, rule or regulation of any Governmental Body to which the Company or Company’s business is subject or (d) any applicable laws or regulations. There is no (with or without the lapse of time or the giving of notice or both) violation or default or, to the knowledge of the Company, threatened violation or default of or under any Company Contract.

 

2.3.2         The Company has complied with all applicable federal and state securities laws and regulations, including being current in all of its reporting obligations under federal securities laws and regulations; and all prior issuances of securities have been either registered under the Securities Act, or exempt from registration. The Company has no Knowledge of any outstanding SEC or FINRA comments and has not received any comments from the SEC or FINRA in the last three years, except as the Company has already discussed with, and/or provided copies of to, OEP.

 

 

 

 

 

  20  
 

 

2.3.3         No order suspending the effectiveness of any registration statement of the Company under the Securities Act or the Exchange Act has been issued by the SEC and, to the Company’s Knowledge, no proceedings for that purpose have been initiated or threatened by the SEC.

 

2.3.4         The Company is not and has not during the past ten years, and the present officers, directors and Affiliates of the Company are not, and have not for the past ten years, been the subject of, nor does any officer or director of the Company have any reason to believe that the Company or any of its officers, directors or Affiliates will be the subject of, any civil or criminal proceeding or investigation by any federal or state agency alleging a violation of securities laws.

 

2.3.5         The Company is not and has not been for the past ten years, the subject of any voluntary or involuntary bankruptcy proceeding, nor is it or has it been a party to any material litigation or, within the past four years, the subject of any threat of material litigation; litigation shall be deemed “ material ” if the amount at issue exceeds the lesser of $10,000 per matter or $25,000 in the aggregate.

 

2.3.6         The Company has not, and the past and present officers, directors and Affiliates of the Company have not, during the last ten years, been the subject of, nor does any officer or director of the Company have any reason to believe that the Company or any of its officers, directors or affiliates will be the subject of, any civil, criminal or administrative investigation or proceeding brought by any federal or state agency.

 

2.3.7         No officer, director or greater than 20% shareholder of the Company is considered a ‘bad actor’ under, or subject to disqualification under, Rule 506(d) of the Securities Act or has been subject to any event which would require disclosure by the Company under Rule 506(e) of the Securities Act in any offering under Regulation D.

 

2.4.             Convertible Securities, Options or Warrants . There are no existing convertible securities, options, warrants, calls, or commitments of any character relating to the authorized and unissued stock of the Company, except as otherwise set forth in the Company Schedules or the Company’s filings with the SEC on EDGAR (which filings can be accessed by going to https://www.sec.gov/search/search.htm, typing “ Panther Biotechnology ” in the “ Company name ” field, and clicking the “ Search ” button).

 

2.5.             Title and Related Matters . The Company has good and marketable title to all of its properties, inventory, interest in properties, and assets, real and personal, free and clear of all Liens, pledges, charges, or Encumbrances except (a) statutory liens or claims not yet delinquent; (b) such imperfections of title and easements as do not and will not materially detract from or interfere with the present or proposed use of the properties subject thereto or affected thereby or otherwise materially impair present business operations on such properties; and (c) as described in the Company Schedules. Except as set forth in the Company Schedules, the Company owns, free and clear of any liens, claims, encumbrances, royalty interests, or other restrictions or limitations of any nature whatsoever, any and all products it is currently manufacturing, including the underlying technology and data, and all procedures, techniques, marketing plans, business plans, methods of management, or other information utilized in connection with the Company’s business. Except as set forth in the Company Schedules, no third party has any right to, and the Company has not received any notice of infringement of or conflict with asserted rights of others with respect to any product, technology, data, trade secrets, know-how, proprietary techniques, trademarks, service marks, trade names, or copyrights which, individually or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would have a materially adverse effect on the business, operations, financial condition, income, or business prospects of the Company or any material portion of its properties, assets, or rights.

 

 

 

 

 

 

  21  
 

 

2.6.             Litigation and Proceedings . There are no actions, suits, proceedings or investigations pending or, to the Knowledge of the Company after reasonable investigation, threatened by or against the Company or affecting the Company or its properties, at law or in equity, before any court or other governmental agency or instrumentality, domestic or foreign, or before any arbitrator of any kind. The Company has no Knowledge of any default on its part with respect to any judgment, order, writ, injunction, decree, award, rule or regulation of any court, arbitrator, or governmental agency or instrumentality, or any circumstance which after reasonable investigation would result in the discovery of such default.

 

2.7.             Approval of Agreement . The Board of Directors of the Company will authorize the execution and delivery of this Agreement by the Company and approve this Agreement and the transactions contemplated hereby prior to the Closing Date.

 

2.8.             Valid Obligation . This Agreement and all agreements and other documents executed by the Company in connection herewith constitute the valid and binding obligation of the Company, enforceable in accordance with its or their terms, except as may be limited by bankruptcy, insolvency, moratorium or other similar laws affecting the enforcement of creditors’ rights generally and subject to the qualification that the availability of equitable remedies is subject to the discretion of the court before which any proceeding therefor may be brought.

 

2.9.             No Other Representations or Warranties . Except for the representations and warranties contained in this ARTICLE II or in any Company Schedule neither the Company, nor any other Person, makes any other express or implied representation or warranty on behalf of the Company nor any of their Affiliates or representatives to OEP or the OEP Members.

 

 

 

 

 

  22  
 

 

2.10.         No Untrue Representation or Warranty . No representation or warranty contained in this Agreement or any attachment, schedule, exhibit, certificate or instrument furnished to OEP or the OEP Members pursuant hereto, or in connection with the transactions contemplated hereby, contains any untrue statement of a material fact, or omits to state any material fact necessary to make the statements contained herein or therein not misleading.

 

ARTICLE III.
PLAN OF EXCHANGE

 

3.1.             The Exchange .

 

3.1.1         On the terms and subject to the conditions set forth in this Agreement, on the Closing Date (as defined below), OEP and the OEP Members shall accept the Exchange Offer described herein and shall assign, transfer and deliver, free and clear of all liens, pledges, encumbrances, charges, restrictions or known claims of any kind, nature, or description, the shares of OEP set forth herein, in the aggregate constituting no less than One Hundred Percent (100%) of the issued and outstanding securities of OEP to the Company at the Closing. The Exchange shall be effective for all purposes as of January 1, 2017.

 

3.1.2         The Company shall accept the Exchange Offer, and shall, on the terms and conditions set forth in this Agreement issue the OEP Members a Non-Recourse Secured Convertible Promissory Note in the aggregate principal amount of $300,000, in the form of Exhibit B hereof (the “ Note ”), which shall be in consideration for One Hundred Percent (100%) of the ownership interests of OEP.

 

3.2.             Closing . The closing (“ Closing ”) of the transaction contemplated by this Agreement shall occur automatically, and without any further required action from any Party, upon the satisfaction of the Closing Conditions (described below) (the “ Closing Date ”) which date shall in no event be later than January 31, 2017 (the “ Required Closing Date ”), unless such date is extended in writing by the mutual consent of all Parties.

 

3.2.1         The following “ Closing Conditions ” shall have occurred, or have been waived by OEP and the Company in writing, prior to the Closing Date:

 

(i)                  The issuance of the Note shall have been approved, and the Note delivered in accordance with Section 3.1 . The Board of Directors of the Company shall have approved the transactions contemplated by this Agreement;

 

(ii)               The OEP Members shall surrender the certificates evidencing One Hundred Percent (100%) of the securities of OEP, duly endorsed with stock powers or notarized signatures of the holders thereof so as to make the Company the sole owner thereof;

 

 

 

 

  23  
 

 

(iii)             OEP shall supply the Company with Minutes of the Managers and Members of OEP approving and consenting to this Agreement and the transactions contemplated herein;

 

(iv)              OEP shall have delivered documentation and agreements relating to and evidencing the assets of OEP and the Intellectual Property to the Company, and all corporate records (including minutes) of OEP and Subsidiary;

 

(v)                The Company shall have executed and delivered a copy of the Note;

 

(vi)              The OEP Members shall have each delivered and executed a Lock-Up, Leak-Out Agreement in the form of Exhibit C hereto (the “ Lock-Ups ”);

 

(vii)           The Company and Rob Estell shall have each delivered an executed form of the Consulting Agreement;

 

(viii)         The Parties shall have delivered all officers certificates, Schedules, exhibits and other documentation and information required pursuant to the terms and conditions of this Agreement; and

 

(ix)              The Company shall have complied with all of the requirements of ARTICLE VI , below and OEP shall have complied with all of the requirements of ARTICLE V , below.

 

3.2.2         Promptly following Closing, the following will occur:

 

(i)                  The Company and OEP shall execute, acknowledge, and deliver (or shall ensure to be executed, acknowledged, and delivered) any and all certificates, schedules, agreements, resolutions, rulings or other instruments required by this Agreement to be so delivered at or prior to the Closing, together with such other items as may be reasonably requested by the Parties hereto and their respective legal counsel in order to effectuate or evidence the transactions contemplated hereby.

 

3.3.             Tradability of Securities . The Securities have not been registered under the Securities Act, nor registered under any state securities Law, and are “ restricted securities ” as that term is defined in Rule 144 under the Securities Act. The securities may not be offered for sale, sold or otherwise transferred except pursuant to an effective registration statement under the Securities Act, or pursuant to an exemption from registration under the Securities Act. The Securities will bear the following restrictive legend:

 

 

 

 

 

 

  24  
 

 

‘‘THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, AND MAY NOT BE SOLD, TRANSFERRED, PLEDGED, OR HYPOTHECATED WITHOUT EITHER: i) REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND APPLICABLE STATE SECURITIES LAWS, OR ii) SUBMISSION TO THE CORPORATION OF AN OPINION OF COUNSEL, SATISFACTORY TO THE CORPORATION THAT SAID SHARES AND THE TRANSFER THEREOF ARE EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933 AND APPLICABLE STATE SECURITIES LAWS.’’

 

3.4.             Termination .

 

3.4.1         The transactions contemplated hereby may be terminated or abandoned at any time prior to the Closing Date:

 

(i)                  by the mutual written consent of the Company and OEP.

 

(ii)               by either the Company, or OEP, on written notice to the other Party if the Closing shall not have occurred on or prior to the Required Closing Date; provided, however, that the right to terminate this Agreement under this Section 3.4.1(ii) shall not be available to any Party whose breach of any provision of this Agreement has been the cause of, or resulted in, the failure of the Closing to occur on or before the Required Closing Date; provided, further, that notwithstanding the previous limitation, the Required Closing Date shall not be extended in perpetuity until such breach is cured, and the non-breaching Party shall be obligated to elect: (x) to close regardless of such breach following a reasonable period of time necessary to cure such breach, or (y) to terminate this Agreement on a date certain to not exceed 12 months from the date hereof, and upon any failure to make such election, this Agreement shall automatically terminate as of the date that is 12 months from the date hereof; or

 

(iii)             by (1) OEP or the OEP Members, upon written notice to the Company if any of the conditions set forth in ARTICLE VI shall have become incapable of fulfillment and shall not have been waived by OEP and where applicable, the OEP Members, or (2) by the Company on written notice to OEP if any of the conditions set forth in ARTICLE V shall have become incapable of fulfillment and shall not have been waived by the Company; provided that the right to terminate this Agreement pursuant to this Section 3.4.1(iii) shall not be available if the failure of the Party so requesting termination to fulfill any obligation under this Agreement shall have been the cause of, or shall have resulted in, the failure of such condition to be satisfied on or prior to such date.

 

 

 

 

 

 

 

  25  
 

 

3.4.2         This Agreement may be terminated by either the Board of Directors of the Company, the Managers of OEP or the OEP Members at any time prior to the Closing Date if:

 

(i)       there shall be any actual or threatened action or proceeding before any court or any Governmental Body which shall seek to restrain, prohibit, or invalidate the transactions contemplated by this Agreement and which, in the judgment of such Board of Directors, Managers or Members, made in good faith and based upon the advice of its legal counsel, makes it inadvisable to proceed with the Exchange; or

 

(ii)               any of the transactions contemplated hereby are disapproved by any regulatory authority whose approval is required to consummate such transactions (which does not include the SEC) or in the judgment of such Board of Directors, Managers or Members, made in good faith and based on the advice of counsel, there is substantial likelihood that any such approval will not be obtained or will be obtained only on a condition or conditions which would be unduly burdensome, making it inadvisable to proceed with the Exchange.

 

In the event of termination pursuant to this paragraph, no obligation, right or liability shall arise hereunder, and each Party shall bear all of the expenses incurred by it in connection with the negotiation, drafting, and execution of this Agreement and the transactions herein contemplated.

 

3.5.             Effect of Termination . In the event of the termination of this Agreement in accordance with this Section 3.4 , this Agreement shall become null and void and of no further force or effect except for ARTICLE VII and ARTICLE VIII which shall survive the termination of this Agreement for any reason. Termination of this Agreement shall not relieve a breaching Party from all breaches of this Agreement that occurred prior to such termination. In no event shall any Party be liable for punitive damages.

 

ARTICLE IV.
SPECIAL COVENANTS

 

4.1.             Access to Properties and Records . The Company and OEP will each afford to the officers and authorized representatives of the other Parties reasonable access to the properties, books and records of the Company or OEP, as the case may be, in order that each may have a full opportunity to make such reasonable investigation as it shall desire to make of the affairs of the other, and each will furnish the other with such additional financial and operating data and other information as to the business and properties of the Company or OEP, as the case may be, as the other shall from time to time reasonably request. Any such investigation and examination shall be conducted at reasonable times and under reasonable circumstances, and each Party hereto shall cooperate fully therein. No investigation by a Party hereto shall, however, diminish or waive in any way any of the representations, warranties, covenants or agreements of the other Party under this Agreement. In order that each Party may investigate as it may wish the business affairs of the other, each Party shall furnish the other during such period with all of such information and copies of such documents concerning the affairs of it as the other Party may reasonably request, and cause its officers, employees, consultants, agents, accountants, and attorneys to cooperate fully in connection with such review and examination, and to make full disclosure to the other Parties all material facts affecting its financial condition, business operations, and the conduct of operations.

 

 

 

 

 

  26  
 

 

4.2.             Delivery of Books and Records and Bank Accounts . At the Closing, OEP shall deliver to the Company copies of the corporate minute books, books of account, contracts, records, and all other books or documents including the bank accounts of OEP now in the possession of OEP or its representatives.

 

4.3.             Third Party Consents and Certificates . The Company and OEP agree to cooperate with each other in order to obtain any required third party consents to this Agreement and the transactions herein contemplated.

 

4.4.             Actions Prior to Closing .

 

4.4.1         From and after the date of this Agreement until the Closing Date and except as set forth in the Company Schedules or the OEP Schedules, or as permitted or contemplated by this Agreement, the Company and OEP, respectively (subject to paragraph (b) below), will each:

 

(i)                  carry on its business in substantially the same manner as it has heretofore;

 

(ii)               maintain and keep its properties in states of good repair and condition as at present, except for depreciation due to ordinary wear and tear and damage due to casualty;

 

(iii)             maintain in full force and effect insurance comparable in amount and in scope of coverage to that now maintained by it;

 

(iv)              use good faith efforts to perform in all material respects all of its obligations under material contracts, leases, and instruments relating to or affecting its assets, properties, and business;

 

(v)                use its good faith efforts to maintain and preserve its business organization intact, to retain its key employees, and to maintain its relationship with its material suppliers and customers; and

 

(vi)              fully comply with and perform in all material respects all obligations and duties imposed on it by all federal, provincial and state laws and all rules, regulations, and orders imposed by federal, provincial or state governmental authorities.

 

 

 

 

 

 

  27  
 

 

4.4.2         From and after the date of this Agreement until the Closing Date OEP will not:

 

(i)                  make any changes in its Articles of Incorporation or Bylaws, except as otherwise provided in this Agreement;

 

(ii)               take any action described in Section 1.6 (all except as permitted therein or as disclosed in OEP’s schedules);

 

(iii)             enter into or amend any contract, agreement, or other instrument except in the ordinary course of business involving the sale of goods or services; or

 

(iv)              sell any assets or discontinue any operations, sell any shares evidencing capital stock (other than as contemplated in this Section 4.4 ), issue any convertible securities or conduct any similar transactions.

 

4.5.             Post-Closing Conditions .

 

4.5.1         Following the Closing, the OEP Members shall assist the Company, at their sole cost and expense, with the preparation of financial statements in accordance with US GAAP, pro forma financial information and such other interim financial information as required by Item 2.01(f) and/or Item 9.01 of Form 8-K and Regulation S-X of the Securities Act, in acceptable form to the Company, as applicable (the “ Financial Statements ”).

 

4.6.             Potential For Earn-Out Consideration .

 

4.6.1         As additional consideration for the OEP Members agreeing to the Exchange and the transactions contemplated herein, and subject to the terms and conditions of this Section 4.6 , the Company shall issue up to a total of 1,000,000 additional shares of common stock (as adjusted for any stock split, recapitalization or dividend)(the “ Earn-Out Shares and together with Note, and the shares of Company common stock issuable upon conversion thereof, the “ Securities ”), to the OEP Members, pro rata with their ownership of OEP as of the Closing Date, as follows:

 

(i)                  The Company shall issue such number of shares of common stock of the Company, not to exceed 1,000,000 shares in aggregate (for both years), as equals the Earn-Out Share Calculation, for the fiscal years ended December 31, 2017 and 2018.

 

 

 

 

 

  28  
 

 

(ii)               The “ Earn-Out Share Calculation ” equals (a) total annual OEP Revenue (for the years ended December 31, 2017 and 2018, as applicable) minus $1,000,000, divided by three, (b) plus total OEP Profit minus $100,000, multiplied by three, multiplied by (c) 0.30.

 

(iii)             In no event will more than 1,000,000 additional Earn-Out Shares be issued or due hereunder.

 

4.6.2         The Earn-Out Shareholders shall be issued the applicable Earn-Out Shares as soon as practicable, subject to applicable rules and regulations and the remainder of this Section 4.6 , after the date that OEP Revenue and OEP Profit is calculated for each of the applicable years.

 

4.6.3         The Company shall maintain separate accounting records relating to the OEP Revenue and OEP Profit, until December 31, 2018 (the “ Earn-Out Period ”). During the Earn-Out Period, the Company agrees (i) to operate OEP in a manner not intentionally designed to reduce or eliminate the amount of the OEP Revenue or OEP Profit, but with due regard for practical business considerations, including with respect to profitability criteria, (ii) to provide products and services to customers and clients of OEP on terms, provisions, pricing, timeliness and quality of service comparable to that provided to the applicable historical standards of OEP generally, and (iii) to not divert sales generation efforts with clients and customers of OEP away from OEP and its sales channels with the sole intent of reducing or eliminating OEP Revenue or OEP Profit. The OEP Members agree that the restrictions stated in this paragraph are limited by the reasonable business considerations of the Company with respect to the operation of OEP. Except for regular maintenance capital expenditures arising in the ordinary course of business, nothing herein shall constitute an obligation on the part of the Company to make any predetermined level of capital expenditures during the applicable Earn-Out Period.

 

ARTICLE V.
CONDITIONS PRECEDENT TO OBLIGATIONS OF THE COMPANY

 

The obligations of the Company under this Agreement are subject to the satisfaction, at or before the Closing Date, of the following conditions, to the extent not waived by the Company in writing:

 

5.1.             Ownership of OEP . Prior to the Closing Date, the OEP Members shall have demonstrated to the Company, with evidence reasonably satisfactory to the Company, that the OEP Members are the owners of One Hundred Percent (100%) of the outstanding securities of OEP.

 

5.2.             Accuracy of Representations and Performance of Covenants . The representations and warranties made by OEP and the OEP Members in this Agreement were true when made and shall be true at the Closing Date with the same force and effect as if such representations and warranties were made at and as of the Closing Date (except for changes therein permitted by this Agreement). OEP and the OEP Members shall have performed or complied with all covenants and conditions required by this Agreement to be performed or complied with by OEP or the OEP Members prior to or at the Closing. The Company shall be furnished with a certificate, signed by a duly authorized executive officer of OEP and dated the Closing Date, to the foregoing effect.

 

 

 

 

  29  
 

 

5.3.             Officer’s Certificate . The Company shall have been furnished with a certificate dated the Closing Date and signed by a duly authorized officer of OEP to the effect that no litigation, proceeding, investigation, or inquiry is pending, or to the best Knowledge of OEP threatened, which might result in an action to enjoin or prevent the consummation of the transactions contemplated by this Agreement, or, to the extent not disclosed in the OEP Schedules, by or against OEP, which might result in any material adverse change in any of the assets, properties, business, or operations of OEP.

 

5.4.             No Material Adverse Change . Prior to the Closing Date, there shall not have occurred any material change in the financial condition, business, or operations of OEP nor shall any event have occurred which, with the lapse of time or the giving of notice, is determined to be unacceptable by the Company in its reasonable discretion.

 

5.5.             Approval by OEP . The Exchange shall have been approved, and securities delivered in accordance with Section 3.1 , by OEP and the OEP Members. The Managers of OEP shall have approved the transactions contemplated by this Agreement.

 

5.6.             No Governmental Prohibition . No order, statute, rule, regulation, executive order, injunction, stay, decree, judgment or restraining order shall have been enacted, entered, promulgated or enforced by any court or governmental or regulatory authority or instrumentality which prohibits the consummation of the transactions contemplated hereby.

 

5.7.             Consents . All consents, approvals, waivers or amendments pursuant to all contracts, licenses, permits, trademarks and other intangibles in connection with the transactions contemplated herein, or for the continued operation of the Company and OEP after the Closing Date on the basis as presently operated shall have been obtained.

 

5.8.             Due Diligence . The Company shall have conducted due diligence on OEP and verified among other things, the rights and liabilities associated with the assets and operations of OEP (the “ Due Diligence ”), which Due Diligence shall be satisfactory to the Company in its sole and absolute discretion. In the event that the Due Diligence is unsatisfactory to the Company, the Company shall have the right to terminate this Agreement and the transactions contemplated hereby without any liability to the Company whatsoever. OEP agrees to afford to the officers and authorized representatives of the Company, reasonable access to the properties, books and records of OEP, as the case may be, in order that it may have a full opportunity to make such reasonable investigation as it shall desire to make of the affairs of OEP and will furnish Company with such additional financial and operating data and other information as to the business, operations and assets of OEP as the Company shall from time to time reasonably request. Any such investigation and examination shall be conducted at reasonable times and under reasonable circumstances, and each Party hereto shall cooperate fully therein. No investigation by a Party hereto shall, however, diminish or waive in any way any of the representations, warranties, covenants or agreements of the other Party under this Agreement.

 

 

 

 

 

 

  30  
 

 

5.9.             Employment and Related Agreements . The Company shall enter into a one year consulting agreement with Rob Estell in the form of Exhibit D attached hereto (the “ Consulting Agreement ”).

 

5.10.         Other Closing Conditions . The closing conditions set forth in Section 3.2.1 shall have occurred.

 

ARTICLE VI.
CONDITIONS PRECEDENT TO OBLIGATIONS OF OEP AND THE OEP MEMBERS

 

The obligations of OEP and the OEP Members under this Agreement are subject to the satisfaction, at or before the Closing Date, of the following conditions, to the extent not waived by the Company and the OEP Members, in writing:

 

6.1.             Accuracy of Representations and Performance of Covenants . The representations and warranties made by the Company in this Agreement were true when made and shall be true as of the Closing Date (except for changes therein permitted by this Agreement) with the same force and effect as if such representations and warranties were made at and as of the Closing Date. Additionally, the Company shall have performed and complied with all covenants and conditions required by this Agreement to be performed or complied with by the Company and shall have satisfied all conditions set forth herein prior to or at the Closing. OEP shall have been furnished with certificates, signed by duly authorized executive officers of the Company and dated the Closing Date, to the foregoing effect.

 

6.2.             Officer’s Certificate . OEP shall have been furnished with a certificate dated the Closing Date and signed by the duly authorized executive officer of the Company, to the effect that no litigation, proceeding, investigation or inquiry is pending, or to the best Knowledge of the Company threatened, which might result in an action to enjoin or prevent the consummation of the transactions contemplated by this Agreement or, to the extent not disclosed in the Company Schedules, by or against the Company, which might result in any material adverse change in any of the assets, properties or operations of the Company.

 

6.3.             No Material Adverse Change . Prior to the Closing Date, there shall not have occurred any change in the financial condition, business or operations of the Company nor shall any event have occurred which, with the lapse of time or the giving of notice, is determined to be unacceptable by OEP or the OEP Members.

 

 

 

 

 

 

 

 

  31  
 

 

6.4.             No Governmental Prohibition . No order, statute, rule, regulation, executive order, injunction, stay, decree, judgment or restraining order shall have been enacted, entered, promulgated or enforced by any court or governmental or regulatory authority or instrumentality which prohibits the consummation of the transactions contemplated hereby.

 

6.5.             Consents . All consents, approvals, waivers or amendments pursuant to all contracts, licenses, permits, trademarks and other intangibles in connection with the transactions contemplated herein, or for the continued operation of the Company and OEP after the Closing Date on the basis as presently operated shall have been obtained.

 

6.6.             Other Closing Conditions . The closing conditions set forth in Section 3.2.1 shall have occurred.

 

ARTICLE VII.
INDEMNIFICATION

 

7.1.             Indemnification by the OEP Members . Subject to the provisions of this Article, the OEP Members agree to jointly and severally indemnify, defend and hold the Company and its Affiliates, parents, stockholders, subsidiaries, officers, directors, employees, agents, successors and assigns (such indemnified persons are collectively hereinafter referred to as “ the Company Indemnified Persons ”), harmless from and against any and all loss, liability, damage or deficiency (including interest, penalties, judgments, costs of preparation and investigation, and attorneys’ fees) (collectively, “ Losses ”) that any of the Company Indemnified Person may suffer, sustain, incur or become subject to arising out of or due to: (a) the non-fulfillment of any covenant, undertaking, agreement or other obligation of OEP or any other Party (other than the Company) under this Agreement or any Schedule hereto; (b) any action taken by OEP prior to the Closing Date, or the operations of OEP prior to Closing; (c) any misstatement, breach of or inaccuracy of any representation of OEP or any OEP Member in this Agreement; (d) the breach of any representation, warranty or covenant of OEP or OEP Member in this Agreement; or (e) any liabilities of OEP which are not disclosed to the Company at or prior to Closing and which the Company is required to satisfy subsequent to Closing (including all fees and expenses associated therewith); provided however, that OEP and the OEP Members will not be liable under clause (d) of this Section 7.1 unless the aggregate amount of Losses exceeds $10,000 (the “ Threshold ”), in which event OEP or OEP Members shall be liable for all Losses up to, including and exceeding the amount of the Threshold. “ Losses ” as used in this Article is not limited to matters asserted by third parties, but includes Losses incurred or sustained in the absence of third party claims. Payment is not a condition precedent to recovery of indemnification for Losses.

 

7.2.             Indemnification by the Company . Subject to the provisions of this Article, the Company agrees to indemnify, defend and hold the OEP Members (the “ OEP Indemnified Persons ”), harmless from and against any and all Losses that any OEP Indemnified Person may suffer, sustain, incur or become subject to arising out of or due to: (a) the non-fulfillment of any covenant, undertaking, agreement or other obligation of the Company under this Agreement or; (b) any action taken by OEP and/or the operations of OEP after the Closing; which, however, does not include any action that was caused by or as a fault of an action which originally occurred prior to the Closing Date or could be partially attributed as a Loss to the Company under Section 7.1 of this Agreement; (c) any misstatement, breach of or inaccuracy of any material representation of the Company in this Agreement; or (d) the breach of any representation, warranty or covenant of the Company in this Agreement provided however, that the Company will not be liable under clause (d) of this Section 7.2 unless the aggregate amount of Losses exceeds the Threshold, in which event the Company shall be liable for all Losses up to, including and exceeding the amount of the Threshold. The Company shall in no event be responsible for indemnifying or defending any affiliates, officers, directors, employees, agents, successors or assigns of OEP or the OEP Members following the Closing for any matter whatsoever.

 

 

 

 

 

 

  32  
 

 

7.3.             Survival of Representations, Warranties and Covenants . The representations, warranties, covenants and other provisions of this Agreement which by their terms or by implication are to have continuing effect after the expiration or termination of this Agreement shall survive the Closing Date or the termination of this Agreement for any reason whatsoever, and shall remain in full force and effect.

 

7.4.             Notice and Opportunity to Defend . If a Claim for Losses is to be made by any Company Indemnified Person or OEP Indemnified Person (any such indemnified person, hereinafter a “ Claimant ”) seeking indemnification hereunder, such Claimant shall notify the indemnifying party or parties (any such indemnifying party, a “ Respondent ”) promptly. If such event involves (a) any claim or (b) the commencement of any action or proceeding by a third person, Claimant shall give Respondent written notice of such claim or the commencement of such action or proceeding as provided above. Delay or failure to so notify Respondent shall only relieve Respondent of its obligation to the extent, if at all, that Respondent is prejudiced by reason of such delay or failure. Respondent shall have a period of 30 days within which to respond thereto. If Respondent accepts responsibility or does not respond within such 30 day period, then Respondent shall be obligated to compromise or defend, at its own expense and by counsel chosen by Respondent, which counsel shall be acceptable to such Company Indemnified Person or OEP Indemnified Person, as the case may be, such matter, and Respondent shall provide Claimant with such assurances as may be reasonably required by Claimant to assure that Respondent will assume and be responsible for the entire liability at issue. If Respondent fails to assume the defense of such matter within said 30 day period, Claimant will (upon delivering notice to such effect to Respondent) have the right to undertake, at Respondent’s cost and expense, the defense, compromise or settlement of such matter on behalf of such Claimant. The Claimant agrees to cooperate with Respondent and its counsel in the defense against any such asserted liability. In any event, Claimant shall have the right to participate at its own expense in the defense of such asserted liability. Any compromise of such asserted liability by Respondent shall require the prior written consent of Claimant, which consent will not be unreasonably withheld and in the event Claimant defends any such asserted liability, then any compromise of such asserted liability by Claimant shall require the prior written consent of Respondent, which consent shall not be unreasonably withheld.

 

 

 

 

 

 

 

  33  
 

 

7.5.             Remedies Exclusive . The remedies conferred by this Article are intended to be exclusive of and shall supersede any other remedy available under law or at equity.

 

7.6.             Emergency Relief . Notwithstanding anything in this Article to the contrary, any Party may seek emergency relief from a court for any remedy that may be necessary to protect any rights or property of such Party pending the establishment of the arbitral tribunal or its determination of the merits of the controversy.

 

7.7.             Right to Set Off . In the event that the Company shall have a claim against any OEP Member for which the Company has not been fully indemnified as contemplated above, the Company shall have the right to set off the amount of such claim against any OEP Member, against any amounts due such OEP Member hereunder or any other agreement or understanding by and between the Company and any OEP Member.

 

ARTICLE VIII.
CONFIDENTIALITY

 

8.1.             Confidentiality . At all times after the Closing, each OEP Member shall retain in strictest confidence, and shall not disclose to any third parties or use for their benefit (other than in order to fulfill the terms and conditions of this Agreement and the transactions contemplated by this Agreement) or for the benefit of others any confidential information comprising or related to the Company or any of the Company’s Affiliates, OEP, or OEP’s property, including its Intellectual Property, including, without limitation, trade secrets, source code, customer lists, marketing plans or strategies, product development techniques or plans, or technologies (collectively “ Confidential Information ”). Confidential Information shall not include information which (i) is or becomes part of the public domain without breach of this Agreement, (ii) was known to the receiving party on a non-confidential basis prior to disclosure by the other party (except in connection with information of OEP, which shall be considered Confidential Information for all purposes), (iii) is independently received by the receiving party without the use of confidential information, or (iv) is explicitly approved for release by written authorization of the disclosing party. In the event that the receiving party is legally required to disclose any confidential information, the receiving party shall promptly notify the disclosing party of such requirement and, if requested by the disclosing party, shall reasonably cooperate in the disclosing party’s efforts to prevent or limit such disclosure.

 

8.2.             Enforceability .

 

8.2.1         It is the desire and intent of the Parties that the provisions of ARTICLE VIII shall be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in which enforcement is sought. If any particular provision or portion of ARTICLE VIII shall be adjudicated to be invalid or unenforceable in any jurisdiction, ARTICLE VIII shall be deemed amended to delete therefrom such provision or portion adjudicated to be invalid or unenforceable, such amendment to apply only with respect to the operation of this Section 8.2 in the particular jurisdiction in which such adjudication is made. OEP and each OEP Member agrees that it would be difficult to measure the damages to Company and its affiliates from the breach by OEP or OEP Members of the provisions of ARTICLE VIII , that injury to the Company from such breach would be impossible to calculate, and that monetary damages would therefore be an inadequate remedy; accordingly, OEP and the OEP Members agree that the Company shall be entitled, in addition to all other remedies it might have, to injunctions or other appropriate orders to restrain any such breach without showing or proving any actual damages.

 

 

 

 

 

  34  
 

 

8.2.2         The undertakings and covenants of OEP and the OEP Members contained in ARTICLE VIII are an integral part of the transactions set forth in this Agreement and the consideration paid by the Company pursuant to this Agreement shall be consideration to include consideration for such undertakings and covenants.

 

ARTICLE IX.
DEFINITIONS

 

9.1.             Certain Definitions . In addition to other terms defined throughout this Agreement, the following terms have the following meanings when used herein:

 

9.1.1         Affiliate ” means, with respect to any Person, any other Person directly or indirectly controlling, controlled by or under common control with such Person, and in the case of any natural Person shall include all relatives and family members of such Person. For purposes of this definition, a Person shall be deemed to control another Person if such first Person and/or any relatives or family members of such first Person directly or indirectly owns or holds five percent (5%) or more of the ownership interests in such other Person. In the case of OEP, each OEP Member is considered an Affiliate of OEP.

 

9.1.2         Claim means any claim (including any product liability, malpractice or errors or omission claim), demand, complaint, cause of action, investigation, inquiry, suit, action, hearing, notice of violation or legal, administrative, arbitrative or other Proceeding.

 

9.1.3         Encumbrance ” means any charge, claim, community or other marital property interest, condition, equitable interest, Lien, option, pledge, security interest, mortgage, right of way, easement, encroachment, servitude, right of first option, right of first refusal or similar restriction, including any restriction on use, voting (in the case of any security or equity interest), transfer, receipt of income or exercise of any other attribute of ownership.

 

 

 

 

 

 

 

 

 

 

 

  35  
 

 

9.1.4         Environmental Law(s) ” means any foreign, federal, state or local statute, regulation, ordinance, or rule of common law as now or hereafter in effect in any way or any other legally binding requirement relating to the environment, natural resources or protection of human health and safety including, without limitation, the Comprehensive Environmental Response, Compensation and Liability Act (42 U.S.C. § 9601 et seq.), the Emergency Planning and Right-To-Know Act (42 U.S.C. § 11101 et seq.), the Hazardous Materials Transportation Act (49 U.S.C. App. § 1801 et seq.), the Solid Waste Disposal Act (42 U.S.C. § 6901 et seq.) (including the Resource Conservation and Recovery Act), the Clean Water Act (33 U.S.C. § 1251 et seq.), the Clean Air Act (42 U.S.C. § 7401 et seq.), the Toxic Substances Control Act (15 U.S.C. § 2601 et seq.), the Federal Insecticide, Fungicide, and Rodenticide Act (7 U.S.C. § 136 et seq.), the Safe Drinking Water Act (42 U.S.C. § 300(f) et seq.), the Lead-Based Paint Exposure Reduction Act (42 U.S.C. § 2681 et seq.), and the Occupational Safety and Health Act (29 U.S.C. § 651 et seq.), and all laws of a similar nature, and the rules and regulations promulgated pursuant thereto, each as amended.

 

9.1.5         Governmental Body ” means any:

 

(i)                  nation, state, county, city, town, borough, village, district or other jurisdiction;

 

(ii)               federal, state, local, municipal, foreign or other government;

 

(iii)             governmental or quasi-governmental authority of any nature (including any agency, branch, department, board, commission, court, tribunal or other entity exercising governmental or quasi-governmental powers);

 

(iv)              multinational organization or body;

 

(v)                body exercising, or entitled or purporting to exercise, any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power; or

 

(vi)              official of any of the foregoing.

 

9.1.6         Intellectual Property ” means (i) all inventions, whether patentable or not patentable, all improvements thereto, and all patents, patent applications (including those listed on Schedule 1.21.3 and patent disclosures, together with all reissues, continuations, continuations-in-part, divisionals, revisions, utility models, extensions and reexaminations thereof, (ii) the websites, URLs, domain names, trade names and trademarks (including registered and unregistered trademarks, service marks and applications thereof used in the business of OEP) including those set forth in Schedule 1.21.3 together with all translations, adaptations, derivations and combinations thereof and including all goodwill associated therewith, and all applications, registrations and renewals in connection therewith, (iii) all copyrightable works, all copyrights and all applications, registrations, renewals and derivatives in connection therewith, (iv) all trade secrets and confidential business information (including ideas, research and development, know-how, formulas, certifications, compositions, manufacturing and production processes and techniques, technical data, designs including advertising designs, logos, drawings, packaging, specifications, customer and supplier lists, pricing and cost information, and business and marketing plans and proposals, (v) all other proprietary rights, and (vii) all copies and tangible embodiments thereof (in whatever form or medium).

 

 

 

 

 

  36  
 

 

9.1.7         Knowledge ” means that:

 

(i)                  A natural Person will be deemed to have Knowledge of a particular fact or other matter if such Person is actually aware of the fact or matter.

 

(ii)               A Person, other than a natural person, will be deemed to have Knowledge of a particular fact or other matter if any natural Person who is serving, or who has at any time served, as a director, officer, partner, employee, agent, executor or trustee of that Person (or in any similar capacity) has, or at any time had, Knowledge of that fact or other matter (as set forth in (i) above).

 

9.1.8         Law ” means any federal, state, local or foreign law (including common law), statute, code, ordinance, rule, regulation or other requirement or rule of law (including but not limited to as related to revenue, labor, or ERISA) of any Governmental Body.

 

9.1.9         Liability ” means with respect to any Person, any liability or obligation of such Person of any kind, character or description, whether known or unknown, absolute or contingent, accrued or unaccrued, disputed or undisputed, liquidated or unliquidated, secured or unsecured, joint or several, due or to become due, vested or unvested, executory, determined, determinable or otherwise, and whether or not the same is required to be accrued on the financial statements of such Person.

 

9.1.10     Liens ” means all liens, pledges, mortgages, security interests, claims, covenants, leases, subleases, charges, conditions, options, rights of first refusal, licenses, easements, servitudes, rights of way, encumbrances or any other restriction or limitation whatsoever.

 

9.1.11     OEP Profit ” means the annual net profit of OEP as calculated by the Company subject to customary generally accepted accounting practices.

 

9.1.12     OEP Revenue ” means annual revenue of OEP as calculated by the Company subject to customary generally accepted accounting practices.

 

9.1.13     PCAOB ” means Public Company Accounting Oversight Board.

 

 

 

 

 

 

 

 

 

  37  
 

 

9.1.14     Person ” means an individual, partnership, corporation, business trust, limited liability company, limited liability partnership, joint stock company, trust, unincorporated association, joint venture or other entity or a Governmental Body.

 

9.1.15     SEC ” means the United States Securities and Exchange Commission.

 

9.1.16     Securities Act ” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

9.1.17     Tax ” means any income, gross receipts, license, payroll, employment, excise, severance, stamp, occupation, premium, property, environmental, windfall profit, customs, vehicle, airplane, boat, vessel or other title or registration, capital stock, franchise, employees’ income withholding, foreign or domestic withholding, social security, unemployment, disability, real property, personal property, sales, use, transfer, value added, alternative, add-on minimum and other tax, fee, assessment, levy, tariff, charge or duty of any kind whatsoever and any interest, penalty, addition or additional amount thereon imposed, assessed or collected by or under the authority of any Governmental Body or payable under any tax-sharing agreement or any other contract.

 

9.2.             Other Definitional Provisions . The Parties acknowledge, confirm and agree that:

 

9.2.1         The language in all parts of this Agreement shall be construed, in all cases, according to its fair meaning.

 

9.2.2         Each Party and its counsel have reviewed and revised this Agreement and that any rule of construction to the effect that any ambiguities are to be resolved against the drafting Party shall not be employed in the interpretation of this Agreement.

 

9.2.3         Terms defined in the singular shall have a comparable meaning when used in the plural, and vice versa.

 

9.2.4         References to any gender include the other genders.

 

9.2.5         The words “ include, ” “ includes ” and “ including ” do not limit the preceding terms or words and shall be deemed to be followed by the words “ without limitation ”.

 

9.2.6         The terms “ hereof ”, “ herein ”, “ hereunder ”, “ hereto ” and similar terms in this Agreement refer to this Agreement as a whole and not to any particular provision of this Agreement.

 

9.2.7         The terms “ day ” and “ days ” mean and refer to calendar day(s).

 

 

 

 

 

  38  
 

 

9.2.8         The terms “ year ” and “ years ” mean and refer to calendar year(s).

 

9.2.9         All references in this Agreement to “ dollars ” or “ $ ” shall mean United States Dollars.

 

9.2.10     Unless otherwise set forth herein, references in this Agreement to (i) any document, instrument or agreement (including this Agreement) (A) includes and incorporates all exhibits, schedules and other attachments thereto, (B) includes all documents, instruments or agreements issued or executed in replacement thereof and (C) means such document, instrument or agreement, or replacement or predecessor thereto, as amended, modified or supplemented from time to time in accordance with its terms and in effect at any given time, and (ii) a particular Law means such Law as amended, modified, supplemented or succeeded, from time to time and in effect at any given time.

 

9.2.11     In the event of any conflict between the provisions of this Agreement and any such Exhibit or Schedule, the provisions of this Agreement shall control.

 

9.2.12     All Article, Section, Exhibit and Schedule references herein are to Articles, Sections, Exhibits and Schedules of this Agreement, unless otherwise specified.

 

ARTICLE X.
MISCELLANEOUS

 

10.1.         No Bankruptcy and No Criminal Convictions . None of the Parties to this Agreement, or their officers, directors or affiliates, promoters, beneficial shareholders, members, or control persons, nor any predecessor thereof have been subject to the following (unless otherwise disclosed in the OEP Schedules or Company Schedules):

 

10.1.1     Any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer within the past ten (10) years;

 

10.1.2     Any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);

 

10.1.3     Being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; and

 

10.1.4     Being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodity Futures Trading Commission to have violated a federal, provincial or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated.

 

 

 

 

 

  39  
 

 

10.2.         Broker/Finder’s Fee . No broker’s or finder’s fee will be paid in connection with the transaction contemplated by this Agreement. The Company, and OEP, each agree to indemnify the other against any claim by any third person for any commission, brokerage, or finder’s fee arising from the transactions contemplated hereby based on any alleged agreement or understanding between the indemnifying party and such third person, whether express or implied from the actions of the indemnifying party.

 

10.3.         Governing Law and Jurisdiction . This Agreement shall be governed by, enforced, and construed under and in accordance with the laws of the United States of America and, with respect to the matters of state law, with the laws of the State of Texas without giving effect to principles of conflicts of law thereunder. Each of the Parties hereby: (a) irrevocably submits to the non-exclusive personal jurisdiction of any Texas court, over any claim arising out of or relating to this Agreement and irrevocably agrees that all such claims may be heard and determined in such Texas court; and (b) irrevocably waives, to the fullest extent permitted by applicable Law, any objection it may now or hereafter have to the laying of venue in any proceeding brought in a Texas court.

 

10.4.         Notices . All notices and other communications hereunder (“ Notices ”) shall be in writing and shall be deemed given if delivered personally, mailed by registered or certified mail (return receipt requested), sent via facsimile or e-mail (with confirmation of transmission) or sent by a nationally recognized overnight courier (providing proof of delivery) to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice):

 

if to the Company, to:

 

Panther Biotechnology, Inc.

Attn: Evan Levine

1517 San Jacinto Street

Houston, Texas 77002

Phone: 858-263-2744

Fax: none

Email: info@pantherbiotechnology.com

 

with a copy to (which shall not constitute notice hereunder):

 

The Loev Law Firm, PC

Attn: David M. Loev, Esq. or John S. Gillies, Esq.

6300 West Loop South, Suite 280

Bellaire, Texas 77401

Phone: (713) 524-4110

Fax: (713) 524-4122

Email: dloev@loevlaw.com; john@loevlaw.com

 

 

 

 

 

  40  
 

 

if to OEP, to:

 

One Exam Prep LLC

4400 Sample Road

Coconut Creek, Florida 33073

Attn: Rob Estell

Phone: 561-441-9932

Fax: none

Email: rob@thepoolpros.com

 

with a copy to (which shall not constitute notice hereunder):

 

if to a OEP Member, to:

 

The address for notice set forth on the signature page hereof

 

or at such other address or number as shall be designated by a Party in a notice to the other Party given in accordance with this Section. Except as otherwise provided in this Agreement, all such communications shall be deemed to have been duly given: (A) in the case of a notice sent by regular or registered or certified mail, three Business Days after it is duly deposited in the mails; (B) in the case of a notice delivered by hand, when personally delivered; (C) in the case of a notice sent by facsimile, upon transmission subject to telephone confirmation of receipt; (D) in the case of a notice sent by email that the computer of the Person sending the email message has generated a receipt evidencing that the recipient has read the email message, upon telephone confirmation of receipt, or upon email reply from the Person to whom the email was sent (i) confirming receipt of the email, or (ii) responding to the email and including the text thereof in the body of the response; and (E) in the case of a notice sent by overnight mail or overnight courier service, upon confirmation of delivery thereof by the United States Postal Service or the reputable overnight courier service, as applicable.

 

10.5.         Attorney’s Fees . In the event that any Party institutes any action or suit to enforce this Agreement or to secure relief from any default hereunder or breach hereof, the prevailing Party shall be reimbursed by the losing Party for all costs, including reasonable attorney’s fees, incurred in connection therewith and in enforcing or collecting any judgment rendered therein.

 

10.6.         Confidentiality . Each Party hereto agrees with the other that, unless and until the transactions contemplated by this Agreement have been consummated, it and its representatives will hold in strict confidence all data and information obtained with respect to another Party or any subsidiary thereof from any representative, officer, director or employee, or from any books or records or from personal inspection, of such other Party, and shall not use such data or information or disclose the same to others (which information shall include the existence of this Agreement and the transactions contemplated herein), except (i) to the extent such data or information is published, is a matter of public knowledge (through no fault or action of the Party holding such information on behalf of the other Party), or is required by a court of competent jurisdiction to be published; or (ii) to the extent that such data or information must be used or disclosed in order to consummate the transactions contemplated by this Agreement. In the event of the termination of this Agreement, each Party shall return to the other Party all documents and other materials obtained by it or on its behalf and shall destroy all copies, digests, work papers, abstracts or other materials relating thereto, and each Party will continue to comply with the confidentiality provisions set forth herein. OEP further agrees and consents to the disclosure by the Company of any material information regarding OEP which the Company or its counsel deems necessary for disclosure in the Company’s public filings on EDGAR in connection with the Company’s current or periodic report filings. The Company shall be required to obtain the prior consent of OEP to publicly disclose such information, which consent shall not be unreasonably withheld, and shall be provided in a timely manner consistent with the Company’s filing obligations under Form 8-K and/or the Securities Act of 1933, as amended or the Securities Act of 1934, as amended, if necessary. The Company shall use its best efforts to avoid the disclosure of any competitive pricing or specific customer information to the public.

 

 

 

 

 

  41  
 

 

10.7.         Publicity . Prior to or after the Closing of the transaction contemplated herein, any announcement, or press or news release by OEP or the OEP Members, Managers, employees, officers, or agents shall be reviewed and approved by the Company prior to its release, subject to any requirements of Law. The Company shall be allowed to make any announcements relating to this Agreement or the transactions contemplated herein, and shall be allowed to file this Agreement and any exhibits or related agreements as may be required pursuant to the Company’s public reporting obligations with the SEC, subject to prior approval by OEP, which approval shall not be unreasonably withheld. Prior to the Closing and prior to the Closing Date, OEP shall make no announcements relating to this Agreement, the Company or the transactions contemplated herein without the prior written consent of the Company, which approval will not be unreasonably withheld.

 

10.8.         Schedules and Exhibits . The Schedules and Exhibits are hereby incorporated into this Agreement and are hereby made a part hereof as if set out in full herein.

 

10.9.         Schedules; Knowledge . Each Party is presumed to have full Knowledge of all information set forth in the other Party’s schedules delivered pursuant to this Agreement and OEP and the OEP Members are deemed to have knowledge of the information set forth in the Company’s EDGAR filings.

 

10.10.     Third Party Beneficiaries . This contract is strictly between the Company, OEP and the OEP Members, and, except as specifically provided, no director, officer, stockholder, employee, agent, independent contractor or any other person or entity shall be deemed to be a third party beneficiary of this Agreement.

 

 

 

 

 

 

 

 

 

  42  
 

 

10.11.     Expenses . The Company and OEP each hereto agree to pay their own costs and expenses incurred in negotiating this Agreement including legal, accounting and professional fees, incurred in connection with the Exchange or any of the other transactions contemplated hereby, and those costs and expenses incurred in consummating the transactions described herein.

 

10.12.     Entire Agreement . This Agreement represents the entire agreement between the Parties relating to the subject matter thereof and supersedes all prior agreements, letters of intent, term sheets, understandings and negotiations, written or oral, with respect to such subject matter.

 

10.13.     Survival; Termination . The representations, warranties, and covenants of the respective Parties shall survive the Closing Date and the consummation of the transactions herein contemplated for a period of two (2) years, unless the terms of this Agreement provide for a longer period of survival.

 

10.14.     Counterparts . This Agreement may be executed in multiple counterparts, each of which shall be deemed an original and all of which taken together shall be but a single instrument.

 

10.15.     Amendment or Waiver . Every right and remedy provided herein shall be cumulative with every other right and remedy, whether conferred herein, at law, or in equity, and may be enforced concurrently herewith, and no waiver by any Party of the performance of any obligation by the other shall be construed as a waiver of the same or any other default then, theretofore, or thereafter occurring or existing. At any time prior to the Closing Date, this Agreement may be amended by a writing signed by all Parties hereto, with respect to any of the terms contained herein, and any term or condition of this Agreement may be waived or the time for performance may be extended by a writing signed by the Party or Parties for whose benefit the provision is intended.

 

10.16.     Best Efforts . Subject to the terms and conditions herein provided, each Party shall use its reasonable best efforts to perform or fulfill all conditions and obligations to be performed or fulfilled by it under this Agreement so that the transactions contemplated hereby shall be consummated as soon as practicable. Each Party also agrees that it shall use its reasonable best efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary, proper or advisable under applicable laws and regulations to consummate and make effective this Agreement and the transactions contemplated herein.

 

10.17.     Remedies . The Parties agree that the covenants and obligations contained in this Agreement relate to special, unique and extraordinary matters and that a violation of any of the terms hereof or thereof would cause irreparable injury in an amount which would be impossible to estimate or determine and for which any remedy at law would be inadequate. As such, the Parties agree that if any Party fails or refuses to fulfill any of its obligations under this Agreement or to make any payment or deliver any instrument required hereunder or thereunder, then any other Party shall have the remedy of specific performance, which remedy shall be cumulative and nonexclusive and shall be in addition to any other rights and remedies otherwise available under any other contract or at law or in equity and to which such Party might be entitled.

 

 

 

 

 

 

 

  43  
 

 

10.18.     Severability . If any term or other provision of this Agreement is invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Agreement shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any Party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the Parties hereto shall negotiate in good faith to modify this Agreement so as to affect the original intent of the Parties as closely as possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled to the extent possible.

 

10.19.     Independent Nature of Sellers’ Obligations and Rights . The obligations of each OEP Member under this Agreement are several and not joint with the obligations of any other OEP Member, and no OEP Member shall be responsible in any way for the performance or non-performance of the obligations of any other OEP Member under this Agreement. Nothing contained herein, and no action taken by any OEP Member pursuant hereto, shall be deemed to constitute the OEP Members as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the OEP Members are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by this Agreement, and each OEP Member has conducted its own diligence review. Each OEP Member shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement, and it shall not be necessary for any other OEP Member to be joined as an additional party in any proceeding for such purpose, subject in each case to the terms and conditions hereof. Each OEP Member has been represented by its own separate legal counsel in its review and negotiation of this Agreement.

 

10.20.     No Presumption from Drafting . This Agreement has been negotiated at arm’s-length between Persons knowledgeable in the matters set forth within this Agreement. Accordingly, given that all Parties have had the opportunity to draft, review and/or edit the language of this Agreement, no presumption for or against any Party arising out of drafting all or any part of this Agreement will be applied in any action relating to, connected with or involving this Agreement. In particular, any rule of law, legal decisions, or common law principles of similar effect that would require interpretation of any ambiguities in this Agreement against the Party that has drafted it, is of no application and is hereby expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner to affect the intentions of the Parties.

 

10.21.     Review and Construction of Documents . Each Party herein expressly represents and warrants to all other Parties hereto that (a) before executing this Agreement, said Party has fully informed itself of the terms, contents, conditions and effects of this Agreement; (b) said Party has relied solely and completely upon its own judgment in executing this Agreement; (c) said Party has had the opportunity to seek and has obtained the advice of its own legal, tax and business advisors before executing this Agreement; (d) said Party has acted voluntarily and of its own free will in executing this Agreement; and (e) this Agreement is the result of arm’s length negotiations conducted by and among the Parties and their respective counsel.

 

 

 

 

 

 

  44  
 

 

10.22.     Headings; Gender . The paragraph headings contained in this Agreement are for convenience only, and shall in no manner be construed as part of this Agreement. All references in this Agreement as to gender shall be interpreted in the applicable gender of the Parties.

 

10.23.     Transaction Expenses . Until Closing, in the event this Agreement is terminated prior to Closing and/or in the event the Exchange does not close, each Party shall be responsible for the payment of any and all of its own expenses, including without limitation the fees and expenses of counsel, accountants and other advisers, arising out of or relating directly or indirectly to the transactions contemplated by this Agreement (“ Transaction Expenses ”).

 

10.24.     Cooperation Following the Closing . Following the Closing, each Party shall deliver to the other Party such further information and documents and shall execute and deliver to the other Party such further instruments and agreements as the other Party shall reasonably request to consummate or confirm the transactions provided for herein, to accomplish the purpose hereof or to assure to the other Party the benefits hereof.

 

10.25.     Counterparts, Effect of Facsimile, Emailed and Photocopied Signatures . This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement. This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .peg or similar attachment to electronic mail (including email) or as an electronic download (any such delivery, an “ Electronic Delivery ”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any Party, each other Party shall re execute the original form of this Agreement and deliver such form to all other Parties. No Party shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such Party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

 

[Remainder of page left intentionally blank. Signature pages follow.]

 

 

 

  45  
 

 

IN WITNESS WHEREOF , the corporate parties hereto have caused this Agreement to be executed by their respective officers, hereunto duly authorized, as of the date first-above written.

 

 

THE COMPANY

 

PANTHER BIOTECHNOLOGY, INC.

 

 

By: /s/ Evan Levine                             

Name: Evan Levine

Title: Chief Executive Officer

 

 

“OEP”

 

ONE EXAM PREP LLC

 

 

By: /s/ Rob Estell                           

Name: Rob Estell

Title: Manager

 

 

 

 

 

[Signature Pages of OEP Members Follow On Attached Pages]

 

 

 

 

  46  
 

 

OEP Members:

 

 

/s/ Rob Estell                                      

Rob Estell

 

_____    Membership Units

Address for notice:______________________________________________

Facsimile for notice:______________________________________________

Email for notice:________________________________________________

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

  47  

Exhibit 10.1

 

THIS NOTE, AND THE SHARES OF COMMON STOCK ISSUABLE UPON CONVERSION OF THIS NOTE (THE “ SECURITIES ”) HAVE BEEN ACQUIRED FOR INVESTMENT PURPOSES ONLY AND MAY NOT BE TRANSFERRED UNTIL (i) A REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ ACT ” OR THE “ SECURITIES ACT ”) SHALL HAVE BECOME EFFECTIVE WITH RESPECT THERETO OR (ii) RECEIPT BY THE COMPANY OF AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER THE ACT IS NOT REQUIRED IN CONNECTION WITH SUCH PROPOSED TRANSFER NOR IS IN VIOLATION OF ANY APPLICABLE STATE SECURITIES LAWS. THIS LEGEND SHALL BE ENDORSED UPON ANY NOTE ISSUED IN EXCHANGE FOR THIS NOTE AND ANY SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE (EXCEPT AS OTHERWISE PROVIDED BELOW).

 

NON-RECOURSE SECURED CONVERTIBLE PROMISSORY NOTE

 

Effective January 20, 2017

 

FOR VALUE RECEIVED , Panther Biotechnology, Inc. , a Nevada corporation (the “ Company ”), hereby promises to pay to the order of Rob Estell , an individual and/or permitted assigns (the “ Holder ”), the aggregate principal amount of $300,000 (the “ Principal ”), upon the terms and conditions hereinafter set forth. This Non-Recourse Secured Convertible Promissory Note is defined herein as the “ Note ” or the “ Promissory Note ”. The “ Effective Date ” of this Note shall be January 20, 2017. The repayment of this Note is secured by the terms of that certain Security and Pledge Agreement by Company in favor of Holder dated on or around the date hereof (the “ Security Agreement ”), a copy of which is attached as Exhibit A hereto. Upon the occurrence of any Event of Default by Company hereunder, the Holder may take action to enforce the Security Interest provided for in the Security Agreement in connection with the Collateral (as defined therein) secured by the Security Agreement.

 

1.                Payment Terms . The Company shall have no obligation to pay the Principal in cash and instead, the Principal amount hereof shall automatically convert into shares of common stock of the Company (“ Common Stock ”), as set forth in Section 3 hereof. The Principal shall not accrue interest.

 

2.                Prepayment . This Note may be prepaid by the Company in whole or part by the Company by payment of the Principal outstanding under this Note, or any portion thereof, in cash to Holder at any time.

 

3.                Automatic Conversions of this Note.

 

(a)                Beginning on the first Business Day which falls thirty (30) days after the Beginning Conversion Date (the day of such applicable month being defined herein the “ Monthly Conversion Day ”), and continuing each calendar month thereafter on the first Business Day to occur after the applicable Monthly Conversion Day, until the Principal amount of this Note is (i) fully converted into Common Stock pursuant to this Section 3 or (ii) fully repaid by the Company in cash, a portion of the Principal shall automatically convert into that number of shares of Common Stock as equals the lesser of (A) the Monthly Conversion Amount divided by the Conversion Price; and (B) the Maximum Percentage (each as applicable, a “ Monthly Conversion ” and the shares of Common Stock issuable in connection with each Monthly Conversion, the “ Monthly Shares ”). “ Business Day ” means a day other than (i) a Saturday, (ii) a Sunday or (iii) a day on which commercial banks in the City of Houston, Texas are authorized or required to be closed for business. The “ Monthly Conversion Amount ” means ten percent (10%) of the total volume of the Company’s Common Stock on the Principal Market for the thirty (30) days prior to such applicable Monthly Conversion Day (as reported by otcmarkets.com or if the Common Stock is not traded on the OTC Market, Nasdaq.com) multiplied by the Conversion Price. The “ Conversion Price ” equals $0.50 per share of Common Stock. The “ Principal Market ” means initially the OTC Pink market and shall also include the OTCQB Market, the NASDAQ Capital Market, the New York Stock Exchange, NYSE MKT, or the NASDAQ National Market, whichever is at the time the principal trading exchange or market for the Common Stock, based upon share volume.

 

 

 

 

  1  
 

 

(b)                The “ Beginning Conversion Date ” means the earlier to occur of (a) the one year anniversary of the Effective Date; and (b) the date the Company, in its sole discretion, provides.

 

(c)                On the first Business Day on or following, the second anniversary of the Effective Date, the then remaining Principal amount of this Note shall automatically convert (the “ Final Conversion ” and together with each Monthly Conversion, a “ Conversion ”) into that number of shares of Common Stock as equals the remaining Principal balance hereof on such date, divided by the Conversion Price, without regard for the Maximum Percentage (the “ Final Shares ” and together with the Monthly Shares, the “ Shares ”).

 

(d)                Following each Conversion, the Company shall issue to the Holder all Shares which such Holder is due in connection with such Conversion and promptly deliver such Shares to the address of Holder which the Company then has on record. The Shares issuable in connection with a Conversion shall be fully-paid, non-assessable shares of Common Stock. Unless the Holder provides a valid opinion from an attorney stating that such Shares can be issued free of restrictive legend, which shall be determined by the Company in its sole discretion, prior to the issuance date of such Shares, such Shares shall be issued with a restrictive legend.

 

(e)                Notwithstanding anything to the contrary set forth herein, upon Conversion of this Note in accordance with the terms hereof the Holder shall not be required to physically surrender this Note to the Company unless the entire unpaid principal amount of this Note is so Converted, provided further that the Holder’s failure to so deliver this Note shall in no way effect any such Conversion. The Company shall maintain records showing the principal amount so Converted and the dates of such Conversions, so as not to require physical surrender of this Note upon each such Conversion. In the event of any dispute or discrepancy, such records of the Company shall be controlling and determinative in the absence of manifest error. Notwithstanding the foregoing, if any portion of this Note is Converted as aforesaid, the Holder may not transfer this Note unless the Holder first physically surrenders this Note to the Company, whereupon the Company will forthwith issue and deliver upon the order of the Holder a new Note of like tenor, registered as the Holder (upon payment by the Holder of any applicable transfer taxes) may request, representing in the aggregate the remaining unpaid Principal amount of this Note. The Holder and any assignee, by acceptance of this Note, acknowledge and agree that, by reason of the provisions of this paragraph, following Conversion of a portion of this Note, the unpaid and unconverted Principal amount of this Note represented by this Note may be less than the amount stated on the face hereof.

 

(f)                 The Company shall be authorized to take whatever action necessary, if any, following the issuance and delivery of the Shares evidencing the final Conversion of this Note to reflect the cancellation of the Note, which shall not require the approval and/or consent of Holder, and provided that by agreeing to the terms and conditions of this Note and the acceptance of the Note, Holder hereby agrees to release the Company from any and all liability whatsoever in connection with the cancellation of the Note following the final Conversion, regardless of the return to the Company of any documentation representing or evidencing the Note (a “ Cancellation ”).

 

 

 

 

  2  
 

 

(g)                Notwithstanding the above, Holder, by accepting this Note hereby covenants that it will, whenever and as reasonably requested by the Company, at its sole cost and expense, do, execute, acknowledge and deliver any and all such other and further acts, deeds, assignments, transfers, conveyances, confirmations, powers of attorney and any instruments of further assurance, approvals and consents as the Company may reasonably require in order to complete, insure and perfect the Cancellation, if such may be reasonably required by the Company.

 

(h)                Conversion calculations pursuant to this Section 3 , shall be rounded to the nearest whole share of Common Stock, and no fractional shares shall be issuable by the Company upon conversion of this Note.

 

(i)                  If the Company at any time or from time to time on or after the Effective Date of the issuance of this Note (the “ Original Issuance Date ”) effects a subdivision of its outstanding Common Stock, the Conversion Price then in effect immediately before that subdivision shall be proportionately decreased, and conversely, if the Company at any time or from time to time on or after the Original Issuance Date combines its outstanding shares of Common Stock into a smaller number of shares, the Conversion Price then in effect immediately before the combination shall be proportionately increased.

 

(j)                  On the date of any Conversion, all rights of any Holder with respect to the amount of this Note converted, will terminate, except only for the rights of any such Holder to receive certificate(s) (if applicable) for the number of Shares which this Note has been Converted.

 

(k)                Except in connection with the Final Conversion, which shall not be subject to this Section 3(k) , the applicable portion of this Note shall not be convertible during any time that, and only to the extent that, the number of Shares to be issued to Holder upon such Conversion, when added to the number of shares of Common Stock, if any, that the Holder otherwise beneficially owns (outside of this Note, and not including any other securities of the Company held by Holder having a provision substantially similar to this paragraph) at the time of such Conversion, would exceed 4.99% (the “ Maximum Percentage ”) of the number of shares of Common Stock of the Company outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon Conversion of this Note held by the Holder, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “ Beneficial Ownership Limitation ”). The provisions of this paragraph shall not be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 3(k) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation.

 

4.                Representations and Warranties of the Company . The Company represents and warrants to Holder as follows:

 

(a)                The execution and delivery by the Company of this Note (i) are within the Company’s corporate power and authority, and (ii) have been duly authorized by all necessary corporate action. Further, the undersigned is a duly authorized representative of the Company who has been authorized by a resolution of the Board of Directors to exercise any and all documents necessary to effectuate the transaction contemplated hereby.

 

 

 

 

 

  3  
 

 

(b)                This Note is a legally binding obligation of the Company, enforceable against the Company in accordance with the terms hereof, except to the extent that (i) such enforceability is limited by bankruptcy, insolvency, reorganization, moratorium or other laws relating to or affecting generally the enforcement of creditors’ rights, and (ii) the availability of the remedy of specific performance or injunctive or other equitable relief is subject to the discretion of the court before which any proceeding therefore may be brought.

 

5.                Events of Default . If an Event of Default (as defined herein or below) occurs (unless all Events of Default have been cured or waived by Holder), Holder may, by written notice to the Company, take any and all actions provided for in the Security Agreement. The following events shall constitute events of default (“ Events of Default ”) under this Note, and/or any other Events of Default defined elsewhere in this Note shall occur:

 

(a)                the Company shall have breached in any respect any material covenant in this Note, and, with respect to breaches capable of being cured, such breach shall not have been cured within ten (10) days following the receipt of written notice of such breach by the Holder to the Company; or

 

(b)                the Company shall: (i) make an assignment for the benefit of creditors, file a petition in bankruptcy, petition or apply to any tribunal for the appointment of a custodian, receiver or a trustee for it or a substantial portion of its assets; (ii) commence any proceeding under any bankruptcy, reorganization, arrangement, readjustment of debt, dissolution or liquidation or statute of any jurisdiction, whether now or hereafter in effect; (iii) have filed against it any such petition or application in which an order for relief is entered or which remains undismissed for a period of ninety (90) days or more; (iv) indicate its consent to, approval of or acquiescence in any such petition, application, proceeding or order for relief or the appointment of a custodian, receiver or trustee for it or a substantial portion of its assets; or (v) suffer any such custodianship, receivership or trusteeship to continue undischarged for a period of ninety (90) days or more; or

 

(c)                the Company shall take any action authorizing, or in furtherance of, any of the foregoing.

 

In case any one or more Events of Default shall occur and be continuing and Holder has provided the Company written notice of such Event of Default, Holder may proceed to protect and enforce its rights to the Security Interest in the Collateral as defined in the Security Agreement entered into by the parties together herewith, but shall not have any other rights hereunder or any other recourse against the Company or its assets.

 

6.                Certain Waivers by the Company . Except as expressly provided otherwise in this Note, the Company and every endorser or guarantor, if any, of this Note waive presentment, demand, notice, protest and all other demands and notices in connection with the delivery, acceptance, performance, default or enforcement of this Note, and assent to any extension or postponement of the time of payment or any other indulgence, to any substitution, exchange or release of collateral available to Holder, if any, and to the addition or release of any other party or person primarily or secondarily liable.

 

7.                Assignment and Transfer by Holder . If and whenever this Note shall be assigned and transferred, or negotiated, including transfers to substitute or successor trustees, in each case subject to applicable law and the availability of an exemption from registration for such transfer, which shall be approved by the Company subject to the Holder providing the Company a legal opinion for such transfer, which opinion shall be reasonably accepted by the Company, the holder hereof shall be deemed the “ Holder ” for all purposes under this Note.

 

 

 

 

  4  
 

 

8.                Amendment . This Note may not be changed orally, but only by an agreement in writing, signed by the party against whom enforcement of any waiver, change, modification or discharge is sought.

 

9.                Governing Law . It is the intention of the parties hereto that the terms and provisions of this Note are to be construed in accordance with and governed by the laws of the State of Texas, except as such laws may be preempted by any federal law controlling the rate of interest which may be charged on account of this Note.

 

10.            Construction . When used in this Note, unless a contrary intention appears: (i) a term has the meaning assigned to it; (ii) “ or ” is not exclusive; (iii) “ including ” means including without limitation; (iv) words in the singular include the plural and words in the plural include the singular, and words importing the masculine gender include the feminine and neuter genders; (v) any agreement, instrument or statute defined or referred to herein or in any instrument or certificate delivered in connection herewith means such agreement, instrument or statute as from time to time amended, modified or supplemented and includes (in the case of agreements or instruments) references to all attachments thereto and instruments incorporated therein; (vi) the words “ hereof ”, “ herein ” and “ hereunder ” and words of similar import when used in this Note shall refer to this Note as a whole and not to any particular provision hereof; (vii) references contained herein to Article, Section, Schedule and Exhibit, as applicable, are references to Articles, Sections, Schedules and Exhibits in this Note unless otherwise specified; (viii) references to “ writing ” include printing, typing, lithography and other means of reproducing words in a visible form, including, but not limited to email; (ix) references to “ dollars ”, “ Dollars ” or “ $ ” in this Note shall mean United States dollars; (x) reference to a particular statute, regulation or Law means such statute, regulation or Law as amended or otherwise modified from time to time; (xi) any definition of or reference to any agreement, instrument or other document herein shall be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein); (xii) unless otherwise stated in this Note, in the computation of a period of time from a specified date to a later specified date, the word “ from ” means “ from and including ” and the words “ to ” and “ until ” each mean “ to but excluding ”; (xiii) references to “ days ” shall mean calendar days; and (xiv) the paragraph headings contained in this Note are for convenience only, and shall in no manner be construed as part of this Note.

 

11.            No Third Party Benefit . The provisions and covenants set forth in this Note are made solely for the benefit of the parties to this Note and are not for the benefit of any other person, and no other person shall have any right to enforce these provisions and covenants against any party to this Note.

 

12.            Jurisdiction, Venue and Jury Trial Waiver . The parties hereby consent and agree that, in any actions predicated upon this Note, venue is properly laid in Texas and that the Circuit Court in and for Harris County, Texas, shall have full subject matter and personal jurisdiction over the parties to determine all issues arising out of or in connection with the execution and enforcement of this Note.

 

13.            WAIVER OF JURY TRIAL . THE COMPANY AND HOLDER HEREBY KNOWINGLY, VOLUNTARILY AND INTENTIONALLY WAIVE THE RIGHT EITHER MAY HAVE TO TRIAL BY JURY IN RESPECT TO ANY LITIGATION BASED HEREON, OR ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS NOTE AND ANY AGREEMENT CONTEMPLATED TO BE EXECUTED IN CONJUNCTION HEREWITH, OR ANY COURSE OF CONDUCT, COURSE OF DEALING, STATEMENTS, (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF EITHER PARTY. THE COMPANY ACKNOWLEDGES THAT THIS WAIVER OF JURY TRIAL IS A MATERIAL INDUCEMENT TO THE HOLDER IN EXTENDING CREDIT TO THE COMPANY, THAT THE HOLDER WOULD NOT HAVE EXTENDED SUCH CREDIT WITHOUT THIS JURY TRIAL WAIVER, AND THAT THE COMPANY HAS BEEN REPRESENTED BY AN ATTORNEY OR HAS HAD AN OPPORTUNITY TO CONSULT WITH AN ATTORNEY IN CONNECTION WITH THIS JURY TRIAL WAIVER AND UNDERSTANDS THE LEGAL EFFECT OF THIS WAIVER.

 

 

 

 

 

 

 

 

  5  
 

 

14.            Non-Recourse . The obligations of the Company under this Note are non-recourse obligations. If the Company fails to comply with any of the provisions of this Note or an Event of Default occurs hereunder, the Holder’s sole remedy shall be to obtain the Collateral (as defined in the Security Agreement), and the Company shall have no further obligation to the Holder under this Note or otherwise. In furtherance thereof, Holder agrees that for payment of this Note it will look solely to the Collateral or such other collateral, if any, it may now or hereafter be given to secure the payment of this Note, and no other assets of the Company shall be subject to levy, execution or other enforcement procedure for the satisfaction of the remedies of Holder, or for any payment required to be made under this Note. By accepting this Note, the Holder agrees that the Collateral and the rights thereto if assumed by the Holder upon the default hereof and pursuant to the terms of the Security Agreement shall fully discharge all of the Company’s obligations hereunder.

 

15.            Notices . Any and all notices, requests or other communications hereunder shall be given in writing and delivered by: (a) regular, overnight or registered or certified mail (return receipt requested), with first class postage prepaid; (b) hand delivery; (c) facsimile transmission; or (d) overnight courier service, to the parties at the addresses or facsimile numbers set forth on the signature page hereof or at such other address or number as shall be designated by either of the parties in a notice to the other party given in accordance with this Section 15 , provided that at least ten (10) days prior written notice shall be given for any change. Except as otherwise provided in this Note, all such communications shall be deemed to have been duly given: (A) in the case of a notice sent by regular or registered or certified mail, three business days after it is duly deposited in the mails; (B) in the case of a notice delivered by hand, when personally delivered; (C) in the case of a notice sent by facsimile, upon transmission subject to telephone confirmation of receipt; and (D) in the case of a notice sent by overnight mail or overnight courier service, the next business day after such notice is mailed or delivered to such courier, in each case given or addressed as aforesaid.

 

16.            Severability . If any term or other provision of this Note is invalid, illegal or incapable of being enforced by any rule of law, or public policy, all other conditions and provisions of this Note shall nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner adverse to any party. Upon such determination that any term or other provision is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Note so as to affect the original intent of the parties as closely as possible in an acceptable manner to the end that transactions contemplated hereby are fulfilled to the extent possible.

 

17.            Entire Agreement . This Note and the Security Agreement constitute the sole and only agreement of the parties hereto and supersedes any prior understanding or written or oral agreements between the parties respecting the subject matter hereof.

 

 

 

[Remainder of page left intentionally blank. Signature page follows.]

 

 

 

 

 

 

 

 

  6  
 

 

IN WITNESS WHEREOF , the undersigned has caused this Non-Recourse Secured Convertible Promissory Note to be executed and delivered as of the date first above written, to be effective as of the Effective Date set forth above.

 

Company

 

Panther Biotechnology, Inc.

 

 

 

/s/ Evan Levine                                        

Evan Levine

Chief Executive Officer

 

Address For Notice:

 

1517 San Jacinto Street

Houston, Texas 77002

 

 

 

Holder

 

 

 

 

/s/ Rob Estell                                      

Rob Estell

 

Address For Notice:

 

4400 Sample Road

Coconut Creek, Florida 33073

 

 

 

 

 

 

 

 

 

  7  

 

Exhibit 10.2

 

SECURITY AND PLEDGE AGREEMENT

 

THIS SECURITY AND PLEDGE AGREEMENT (this “ Agreement ”), dated as of January 20, 2017, is by and between Panther Biotechnology, Inc., a Nevada corporation (“ Grantor ”), and Rob Estell , an individual (“ Secured Party ”), whose addresses are set forth on the signature page hereof.

 

RECITALS

 

A.        The Grantor owes the Secured Party $300,000 pursuant to a Non-Recourse Secured Convertible Promissory Note dated January 20, 2017 (the “ Note ”), and capitalized terms used herein, but not otherwise defined herein shall have the meanings given to such terms in the Note;

 

C.        A requirement of providing the Note was that Grantor would provide the Secured Party the security interest set forth herein;

 

D.        The Secured Party would not have agreed to enter into the Note but for the Grantor agreeing to grant the Secured Party the Security Interest set forth herein; and

 

E .       In order to induce the Secured Party to provide the Note to Secured Party, Grantor is willing to enter into this Agreement with the Secured Party to secure payment of the amounts due under the Note (the “ Indebtedness ”).

 

NOW, THEREFORE , the parties hereto agree as follows:

 

1.                   Grant of Security Interest .

 

(a)                As collateral security for the prompt and complete payment and performance of all of the Indebtedness (collectively, the “ Obligations ”), Grantor hereby grants a continuing first lien upon, an unqualified right to possession and disposition of and a right of set-off against, in each case to the fullest extent permitted by law, all of its right, title and interest in, to and under the Collateral as defined in Section 1(b) , below (the “ Security Interest ”).

 

(b)                Collateral ” means all right, title and interest in 100% of the membership interests of One Exam Prep LLC , a Florida limited liability company (the “ Company ”), held by Grantor.

 

2.                   Covenants and Warranties . Grantor represents, warrants, covenants and agrees as follows:

 

(a)                The Grantor has the requisite corporate power and authority to enter into this Agreement and otherwise to carry out its obligations thereunder. The execution, delivery and performance by the Grantor of this Agreement has been duly authorized by all necessary action on the part of the Grantor and no further action is required by the Grantor. This Agreement constitutes a legal, valid and binding obligation of the Grantor enforceable in accordance with its terms, except as enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the enforcement of creditor’s rights generally.

 

(b)                The Grantor is the sole owner of the Collateral, free and clear of any liens, security interests, encumbrances, rights or claims, except for liens, encumbrances and claims authorized by the Grantor or existing on the Collateral at the time acquired by the Grantor and is fully authorized to grant the Security Interest in and to pledge the Collateral. There is not on file in any governmental or regulatory authority, agency or recording office an effective financing statement, Security and Pledge Agreement, license or transfer or any notice of any of the foregoing (other than those that have been filed in favor of the Secured Party pursuant to this Agreement) covering or affecting any of the Collateral. So long as this Agreement shall be in effect, the Grantor shall not execute and shall not knowingly permit to be on file in any such office or agency any such financing statement or other document or instrument (except to the extent filed or recorded in favor of the Secured Party, if the rights under such financing statement will subsequently be assigned to the Secured Party, each pursuant to the terms of this Agreement), except with the prior approval of the Secured Party, which shall not be unreasonably withheld, conditioned or delayed.

 

 

 

 

  1  
 

 

(c)                This Agreement creates in favor of the Secured Party a valid security interest in the Collateral securing the payment and performance of the Obligations.

 

(d)                The execution, delivery and performance of this Agreement does not conflict with or cause a breach or default, or an event that with or without the passage of time or notice, shall constitute a breach or default, under any agreement to which the Grantor is a party or by which the Grantor is bound. No consent is required for the Grantor to enter into and perform its obligations hereunder.

 

(e)                The Grantor shall at all times maintain the liens and Security Interest provided for hereunder as valid and perfected first priority liens and security interests in the Collateral in favor of the Secured Party until this Agreement and the Security Interest hereunder shall terminate. The Grantor hereby agrees to defend the same against any and all persons. At the request of the Secured Party, the Grantor will sign and deliver to the Secured Party at any time or from time to time one or more financing statements pursuant to the UCC (or any other applicable statute) in form reasonably satisfactory to the Secured Party and will pay the cost of filing the same in all public offices wherever filing is, or is deemed by the Secured Party to be, necessary or desirable to effect the rights and obligations provided for herein. Without limiting the generality of the foregoing, the Grantor shall pay all fees, taxes and other amounts necessary to maintain the Collateral and the Security Interest hereunder, and the Grantor shall obtain and furnish to the Secured Party from time to time, upon demand, such releases and/or subordinations of claims and liens which may be required to maintain the priority of the Security Interest hereunder.

 

(f)                 Without the prior written consent of Secured Party, Grantor agrees that Grantor will not sell, assign, transfer, exchange, or otherwise dispose of, or grant any option with respect to, the Collateral, nor will Grantor create, incur or permit to exist any pledge, lien, mortgage, hypothecation, security interest, charge, option or any other encumbrance with respect to any of the Collateral, or any interest therein, or any proceeds thereof, except with the prior approval of the Secured Party, which shall not be unreasonably withheld, conditioned or delayed.

 

(g)                The Grantor shall, within ten (10) days of obtaining knowledge thereof, advise the Secured Party promptly, in sufficient detail, of the occurrence of any event which would have a material adverse effect on the value of the Collateral or on the Secured Party’s security interest therein.

 

(h)                The Grantor shall promptly execute and deliver to the Secured Party such further deeds, mortgages, assignments, Security and Pledge Agreements, financing statements or other instruments, documents, certificates and assurances and take such further action as the Secured Party may from time to time request and may in its sole discretion deem necessary to perfect, protect or enforce its security interest in the Collateral.

 

 

 

 

 

 

 

 

  2  
 

 

(i)                  The Grantor shall promptly notify the Secured Party in sufficient detail upon becoming aware of any attachment, garnishment, execution or other legal process levied against any Collateral and of any other information received by the Grantor that may materially affect the value of the Collateral, the Security Interest or the rights and remedies of the Secured Party hereunder.

 

3.                   Rights and Powers of Secured Party . Secured Party, after an Event of Default under the Note, without liability to Grantor may: take ownership of the Collateral and transfer any of the Collateral or evidence thereof into its own name or that of its nominee.

 

4.                   Rights and Powers of Grantor . Without limiting any other rights of the Grantor hereunder or under applicable law, the Grantor:

 

(a)                Shall be permitted to hold the certificate(s) evidencing the Collateral and exercise all voting rights with respect to the Collateral, subject to Secured Party’s rights upon an Event of Default as described herein; provided, however, that no vote shall be cast or other action taken which would impair the Security Interest or which would be inconsistent with or result in any violation of any provision of this Agreement;

 

(b)                Shall own and control all economic rights of the Collateral, subject to Secured Party’s rights upon an Event of Default as described herein, including, but not limited to all rights to dividends paid or payable other than in cash, in respect of, and instruments and other property received, receivable or otherwise distributed in respect of, or in exchange for, the Collateral, dividends and other distributions paid or payable in cash in respect of the Collateral, and cash paid, payable or otherwise distributed in redemption of, or in exchange for, any Collateral; and

 

(c)                Shall be the sole owner of the Collateral, having good and marketable title thereto, free and clear of any and all liens, except for the Security Interest granted to Secured Party pursuant to this Agreement.

 

5.                   Further Assurances; Attorney in Fact .

 

(a)                On a continuing basis, Grantor will make, execute, acknowledge and deliver, and file and record in the proper filing and recording places in the United States, all such instruments, including appropriate financing and continuation statements and collateral agreements and filings, and take all such action as may reasonably be deemed necessary or advisable to perfect the Secured Party’s security interest in the Collateral and otherwise to carry out the intent and purposes of this Agreement.

 

(b)                Grantor hereby irrevocably appoints the Secured Party as Grantor’s attorney in fact, with full authority in the place and stead of Grantor and in the name of Grantor, from time to time upon the occurrence of an Event of Default which is continuing, in the discretion of the Secured Party, to take any action and to execute any instrument which the Secured Party may deem necessary or advisable to accomplish the purposes of this Agreement, including to file, in the sole discretion of the Secured Party, one or more financing or continuation statements and amendments thereto, relative to any of the Collateral without the signature of Grantor where permitted by law. To the extent permitted by law, the Grantor ratifies all that said attorneys will lawfully do or cause to be done by virtue hereof, provided that Grantor shall have no power or authority to exercise the rights described in this Section unless an Event of Default has occurred and is continuing. This power of attorney is a power coupled with an interest and is irrevocable.

 

 

 

 

 

  3  
 

 

6.                   No Waiver by the Secured Party; Cumulative Remedies . The Secured Party will not be deemed to have waived any of their rights or remedies in respect of the Indebtedness or the Collateral unless such waiver is in writing and signed by the Secured Party. No delay or omission on the part of the Secured Party in exercising any right or remedy will operate as a waiver of such right or remedy or any other right or remedy. A waiver on any one occasion may not be construed as a bar to or waiver of any right or remedy on any future occasion.

 

7.                   Term of Agreement . This Agreement, the Security Interest and any and all rights and powers granted to Secured Party under this Agreement, shall terminate automatically on the date on which the balance of the Note is $150,000 or less (the “ Termination Date ”). Secured Party hereby irrevocably constitutes and appoints Grantor and any officer or agent thereof, with full power of substitution, as its true and lawful attorney-in-fact with full irrevocable power and authority in place and stead of Secured Party and in the name of Secured Party or in his own name, immediately upon the Termination Date, for the exclusive purpose of filing (a) a Termination Statement on Form UCC 3 (or any successor form) and (b) any other documents necessary or desirable to evidence the termination of any and all security interests held by Secured Party.

 

8.                   Notices . All notices, requests, demands and other communications hereunder shall be in writing.

 

9.                   Governing Law; Consent to Jurisdiction . THIS AGREEMENT IS GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF TEXAS. The Grantor agrees that any action or claim arising out of, or any dispute in connection with, this Agreement, any rights, remedies, obligations, or duties hereunder, or the performance or enforcement hereof or thereof, may be brought in the courts of the State or any federal court sitting in Harris County, Texas and consents to the exclusive jurisdiction of such courts and to service of process in any such suit being made upon the Grantor by mail at the address for notice to the Grantor set out above.

 

10.               Waiver of Jury Trial . THE GRANTOR WAIVES ITS RIGHT TO A JURY TRIAL WITH RESPECT TO ANY ACTION OR CLAIM ARISING OUT OF ANY DISPUTE IN CONNECTION WITH THIS AGREEMENT, ANY RIGHTS, REMEDIES, OBLIGATIONS, OR DUTIES HEREUNDER, OR THE PERFORMANCE OR ENFORCEMENT HEREOF OR THEREOF. Except as prohibited by law, the Grantor waives any right which it may have to claim or recover in any litigation referred to in the preceding sentence any special, exemplary, punitive or consequential damages or any damages other than, or in addition to, actual damages. The Grantor (i) certifies that neither the Secured Party nor any representative of the Secured Party or attorney of the Secured Party has represented, expressly or otherwise, that the Secured Party would not, in the event of litigation, seek to enforce the foregoing waivers or other waivers contained in this Agreement, and (ii) acknowledges that, the Secured Party is relying upon, among other things, the waivers and certifications contained in this Section.

 

11.               Miscellaneous . The headings of each section of this Agreement are for convenience only and do not define or limit the provisions thereof. This Agreement and all rights and obligations hereunder are binding upon the Grantor and the Grantor’s respective successors and permitted assigns, and inure to the benefit of the Secured Party, Secured Party and the Secured Party’s successors and assigns. If any term of this Agreement is held to be invalid, illegal or unenforceable, the validity of all other terms hereof will in no way be affected thereby, and this Agreement will be construed and be enforceable as if such invalid, illegal or unenforceable term had not been included herein. The Grantor acknowledges receipt of a copy of this Agreement.

 

 

 

 

 

 

 

 

 

 

 

  4  
 

 

12.               Counterparts . This Agreement may be executed in any number of counterparts, each of which when so executed shall be deemed to be an original and, all of which taken together shall constitute one and the same Agreement. In the event that any signature is delivered by facsimile transmission, such signature shall create a valid binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature were the original thereof.

 

IN WITNESS WHEREOF , intending to be legally bound, the Grantor and the Secured Party have caused this Agreement to be duly executed as of the date first above written.

 

GRANTOR

 

Panther Biotechnology, Inc.

 

 

/s. Evan Levine                                       

Evan Levine

Chief Executive Officer

 

Address For Notice:

 

1517 San Jacinto Street

Houston, Texas 77002

 

 

 

 

SECURED PARTY

 

 

 

 

/s/ Rob Estell                                       

Rob Estell

 

Address For Notice:

 

4400 Sample Road

Coconut Creek, Florida 33073

 

 

 

 

 

 

 

 

 

  5  

 

Exhibit 10.3

 

CONSULTING AGREEMENT

 

THIS CONSULTING AGREEMENT (this “ Agreement ”) is made this 24th day of January 2017, by and between Panther Biotechnology, Inc., a Nevada corporation (the “ Company ”), and Rob Estell, an individual (the “ Consultant ”) (each of the Company and Consultant is referred to herein as a “ Party ”, and collectively referred to herein as the “ Parties ”).

 

W I T N E S S E T H:

 

WHEREAS , the Company desires to obtain the services of Consultant, and Consultant desires to provide consulting services to the Company upon the terms and conditions hereinafter set forth.

 

NOW, THEREFORE , in consideration of the premises, the agreements herein contained and other good and valuable consideration, receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as of the Effective Date as follows:

 

ARTICLE I.
ENGAGEMENT; TERM; SERVICES

 

1.1.            Services . Pursuant to the terms and conditions hereinafter set forth, the Company hereby engages Consultant, and Consultant hereby accepts such engagement, to provide services to the Company as reasonably requested by the Company during the Term of this Agreement in connection with the management of operations, sales management and content creating management (the “ Services ”).

 

1.2.            Term . Consultant shall begin providing Services hereunder on January 1, 2017 (the “ Effective Date ”), and this Agreement shall remain in effect until December 31, 2020 (the “ Term ”), provided the Company shall be able to terminate this Agreement with ten (10) days prior notice upon the material breach of any term or condition hereof by the Consultant, and this Agreement shall terminate (a) immediately upon the death or disability of Consultant; or (b) ninety days after written notice of a Party’s intention to terminate this Agreement is provided to the non-terminating Party.

 

1.3.            Allocation of Time and Energies . The Consultant hereby promises to perform and discharge faithfully the Services which may be requested from the Consultant from time to time by the Company and duly authorized representatives of the Company. The Consultant shall provide the Services required hereunder in a diligent and professional manner.

 

ARTICLE II.
CONSIDERATION; EXPENSES

 

2.1.            Consideration . During the Term of this Agreement, for all Services rendered by Consultant hereunder and all covenants and conditions undertaken by the Parties pursuant to this Agreement, the Company shall pay, and Consultant shall accept, as compensation $1,500 per week during the first year of the Term of this Agreement; $1,575 per week during the second year of the Term of this Agreement; and $1,653.75 per week during the third year of the Term of this Agreement (collectively, the “ Consulting Fee ”), payable weekly in arrears.

 

 

 

  1  
 

 

2.2.            Bonus .

 

2.2.1        The Consultant shall be paid a signing bonus (the “ Signing Bonus ”) of $60,000 in connection with his entry into this Agreement, of which $15,000 shall be paid on or before each of April 30, 2017, May 30, 2017, June 30, 2017 and July 30, 2017.

 

2.2.2        In addition to the Consulting Fee and Signing Bonus, on June 30 th and December 31 st , of each year during the Term, the Consultant shall be eligible to earn a bonus payment equal to (a) Total Additional Revenue divided by 100; plus (b) Total Additional Profits divided by 100 (the “ Bonus ”). “ Total Additional Revenue ” equals Total Revenue for the prior six month period minus Base Revenue. “ Total Additional Profits ” equals Total Profits for the prior six month period minus Base Profits. “ Base Revenue ” shall initially be $500,000, but shall increase from time to time in the event the Company (or any subsidiary) acquires any companies, assets, rights or licenses, in the same business space as One Exam Prep LLC (each a “ Related Company ”), in an amount equal to the total Revenue of the Related Company for prior 12 month period divided by two. “ Base Profits ” shall initially be $37,500, but shall increase from time to time in the event the Company (or any subsidiary) acquires any Related Company, in an amount equal to the total Profits of the Related Company for prior 12 month period divided by two. “ Revenue ” means total revenue less (i) returns, (ii) discounts, (iii) adjustments, and (iv) allowances, calculated by the Company subject to customary generally accepted accounting practices. “ Profit ” means gross profit calculated by the Company subject to customary generally accepted accounting practices. The Company shall calculate the Bonus as soon as practicable after each June 30 th and December 31 st , during the Term, and pay the Consultant any Bonus due promptly after such calculation is made. “ Total Revenue ” means gross sales collected by the Company, relating solely to the operations of One Exam Prep LLC [plus any Related Companies], less (i) returns, (ii) discounts, (iii) adjustments, and (iv) allowances, calculated by the Company subject to customary generally accepted accounting practices, rounded down to the nearest multiple of $250,000 (for example, $1,900,000 is rounded down to $1,750,000 and $240,000 is rounded down to $0, similarly, ($1,300,000) would be rounded down to ($1,250,000)). “ Total Profits ” means net profit of One Exam Prep LLC [plus any Related Companies], as calculated by the Company subject to customary generally accepted accounting practices, rounded down to the nearest multiple of $25,000 (for example, $890,000 is rounded down to $875,000 and $24,000 is rounded down to $0, similarly, ($290,000) would be rounded down to ($275,000)). In the event that Total Revenue or Total Profits are negative, they shall decrease the applicable Bonus, provided that the Bonus shall in no event be less than $0, provided further that any negative Bonus calculation for any period ending June 30 th , shall carry over and adjust downward any positive Bonus for any period ending December 31st.

 

2.3.            Expenses . The Company agrees to reimburse Consultant for his reasonable, documented out-of-pocket expenses associated with the Services (the “ Expenses ”), subject to the Company’s normal and usual reimbursement policies, provided that the Consultant shall receive written authorization of any one-time Expense greater than $1,000.

 

 

 

  2  
 

 

 

ARTICLE III.
TERMINATION

 

3.1.            Termination . This obligations under this Agreement shall begin on the Effective Date and continue to bind the Parties until the end of the Term, or the earlier termination thereof as discussed in Section 1.2 .

 

3.2.            Rights Upon Termination . Upon termination of the Term, the Consultant shall continue to comply with the terms of ARTICLE IV hereof following the Termination Date.

 

ARTICLE IV.
CONFIDENTIAL/TRADE SECRET INFORMATION;
COMPANY PROPERTY; NON-SOLICITATION

 

4.1.            Confidential/Trade Secret Information/Non-Disclosure/Non-Solicitation .

 

4.1.1        Confidential/Trade Secret Information Defined . During the course of Consultant’s engagement, Consultant will have access to various Confidential/Trade Secret Information of the Company and information developed for the Company. For purposes of this Agreement, the term “ Confidential/Trade Secret Information ” is information that is not generally known to the public and, as a result, is of economic benefit to the Company in the conduct of its business, and the business of the Company’s subsidiaries. Consultant and the Company agree that the term “ Confidential/Trade Secret Information ” includes but is not limited to all information developed or obtained by the Company, including its affiliates, and predecessors, and comprising the following items, whether or not such items have been reduced to tangible form (e.g., physical writing, computer hard drive, disk, tape, etc.): all methods, techniques, processes, ideas, research and development, product designs, engineering designs, plans, models, production plans, business plans, add-on features, trade names, service marks, slogans, forms, pricing structures, business forms, marketing programs and plans, layouts and designs, financial structures, operational methods and tactics, cost information, the identity of and/or contractual arrangements with suppliers and/or vendors, accounting procedures, and any document, record or other information of the Company relating to the above. Confidential/Trade Secret Information includes not only information directly belonging to the Company which existed before the date of this Agreement, but also information developed by Consultant for the Company, including its subsidiaries, affiliates and predecessors, during the term of Consultant’s engagement with the Company. Confidential/Trade Secret Information does not include any information which (a) was in the lawful and unrestricted possession of Consultant prior to its disclosure to Consultant by the Company, its subsidiaries, affiliates or predecessors, except for information relating to One Exam Prep LLC, or owned thereby, which shall be included in Confidential/Trade Secret Information, (b) is or becomes generally available to the public by lawful acts other than those of Consultant after receiving it, or (c) has been received lawfully and in good faith by Consultant from a third party who is not and has never been a Consultant of the Company, its subsidiaries, affiliates or predecessors, and who did not derive it from the Company, its subsidiaries, affiliates or predecessors.

 

4.1.2        Restriction on Use of Confidential/Trade Secret Information . Consultant agrees that his use of Confidential/Trade Secret Information is subject to the following restrictions for an indefinite period of time so long as the Confidential/Trade Secret Information has not become generally known to the public:

 

 

 

 

 

  3  
 

 

(i)                  Non-Disclosure . Consultant agrees that it will not publish or disclose, or allow to be published or disclosed, Confidential/Trade Secret Information to any person without the prior written authorization of the Company unless pursuant to or in connection with Consultant’s job duties to the Company under this Agreement; and

 

(ii)                Non-Removal/Surrender . Consultant agrees that it will not remove any Confidential/Trade Secret Information from the offices of the Company or the premises of any facility in which the Consultant is performing Services, except pursuant to his duties under this Agreement. Consultant further agrees that it shall surrender to the Company all documents and materials in his possession or control which contain Confidential/Trade Secret Information and which are the property of the Company upon the termination of his engagement with the Company, and that it shall not thereafter retain any copies of any such materials.

 

4.2.            Non-Solicitation of Employees and Consultants . Consultant agrees that during the Term and for the twelve-month period following the date of the termination of this Agreement (the “ Termination Date ”), he shall not, directly or indirectly, solicit or otherwise encourage any employees or consultants of the Company to leave the employ or service of the Company, or solicit, directly or indirectly, any of the Company’s employees or consultants for employment or service; provided, however, that Consultant may solicit an employee or consultant if (i) such employee or consultant has resigned voluntarily (without any solicitation from Consultant), and at least one (1) year has elapsed since such employee’s or consultant’s resignation from employment or termination of service with the Company, (ii) such employee’s employment or consultant’s services was terminated by the Company, and if one (1) year has elapsed since such employee or consultant was terminated by the Company, (iii) the Company has consented to the solicitation of such employee or consultant in writing, which consent the Company may withhold in its sole discretion, or (iv) such solicitation solely occurs by general solicitations for employment to the public.

 

4.3.            Non-Solicitation of Contacts . Consultant agrees that during the Term and during the twelve-month period following the Termination Date, Consultant shall not: (a) interfere with the Company’s business relationship with its customers or suppliers, or (b) solicit, directly or indirectly, or otherwise encourage any of the Company’s customers or suppliers to terminate their business relationship with the Company.

 

4.4.            Breach of Provisions . If Consultant materially breaches any of the provisions of this ARTICLE IV, or in the event that any such breach is threatened by Consultant, in addition to and without limiting or waiving any other remedies available to the Company at law or in equity, the Company shall be entitled to immediate injunctive relief in any court, domestic or foreign, having the capacity to grant such relief, to restrain any such breach or threatened breach and to enforce the provisions of this ARTICLE IV.

 

4.5.            Reasonable Restrictions . The Parties acknowledge that the foregoing restrictions, as well as the duration and the territorial scope thereof as set forth in this ARTICLE IV, are under all of the circumstances reasonable and necessary for the protection of the Company and its business.

 

 

 

 

 

  4  
 

 

4.6.            Specific Performance . Consultant acknowledges and agrees that the Company’s remedies at law for a breach or threatened breach of any of the provisions of ARTICLE IV would be inadequate and, in recognition of this fact, Consultant agrees that, in the event of such a breach or threatened breach, in addition to any remedies at law, the Company, without posting any bond, shall be entitled to obtain equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction or any other equitable remedy which may then be available.

 

4.7.            Company Property . Upon termination of this Agreement, or on demand by the Company during the Term of this Agreement, Consultant will immediately deliver to the Company, and will not keep in his possession, recreate or deliver to anyone else, any and all Company property, records, data, notes, notebooks, reports, files, proposals, lists, correspondence, specifications, drawings blueprints, sketches, materials, photographs, charts, all documents and property, and reproductions of any of the aforementioned items that were developed by Consultant pursuant to the terms of this Agreement, obtained by Consultant in connection with the provision of the Services, or otherwise belonging to the Company or its successors or assigns.

 

ARTICLE V.  

MUTUAL REPRESENTATIONS, COVENANTS AND

WARRANTIES OF THE PARTIES

 

5.1.            Power and Authority . The Parties have all requisite power and authority, corporate or otherwise, to execute and deliver this Agreement and to consummate the transactions contemplated hereby and thereby. The Parties have duly and validly executed and delivered this Agreement and will, on or prior to the consummation of the transactions contemplated herein, execute, such other documents as may be required hereunder and, assuming the due authorization, execution and delivery of this Agreement by the Parties hereto and thereto, this Agreement constitutes, the legal, valid and binding obligation of the Parties enforceable against each Party in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, moratorium or similar laws affecting the Parties rights generally and general equitable principles.

 

5.2.            Execution and Delivery . The execution and delivery by the Parties of this Agreement and the consummation of the transactions contemplated hereby and thereby do not and shall not, by the lapse of time, the giving of notice or otherwise: (a) constitute a violation of any law; or (b) constitute a breach or violation of any provision contained in the Articles of Incorporation or Bylaws, or such other document(s) regarding organization and/or management of the Parties, if applicable; or (c) constitute a breach of any provision contained in, or a default under, any governmental approval, any writ, injunction, order, judgment or decree of any governmental authority or any contract to which the Parties are bound or affected.

 

 

 

 

 

  5  
 

 

5.3.            Authority of Entities . Any individual executing this Agreement on behalf of an entity has authority to act on behalf of such entity and has been duly and properly authorized to sign this Agreement on behalf of such entity.

 

ARTICLE VI.

WORK PRODUCT

 

6.1.            Work Made for Hire . Consultant hereby agrees that all information, materials, tools, data, inventions, ideas, writings and other property, including, without limitation any improvements or modifications, whether or not copyrightable, created or adapted by it, whether alone or in conjunction with any other person, firm or corporation (hereinafter referred to as “ Person ”) arising out of or created in connection with Services, provided for the Company hereunder or as a result of such Services (the “ Work Product ”), whether or not eligible for patent, copyright, trademark, trade secret or other legal protection, shall be “ work made for hire ” for the Company within the meaning of the United States Copyright Act of 1976 and for all other purposes and as such, the sole and exclusive property of the Company.

 

6.2.            License of Work Product . Consultant acknowledges that the Company in its sole discretion shall have the right to license the Work Product or any portion thereof, and/or incorporate the Work Product or any portion thereof into the Company’s products, for use by other licensees or clients of the Company.

 

6.3.            Right to Work Product . Consultant hereby assigns exclusively to the Company in perpetuity, all right, title and interest of any kind whatsoever, in and to the Work Product, including any and all patents, patent rights, trademarks, mask work rights, trade secrets, rights of priority, copyrights and other proprietary rights thereto (and the exclusive right to register copyrights, patents, trademarks and other rights), and represents and warrants that Consultant has not previously assigned such rights or any portion thereof to any other Person. Accordingly, all rights in and to the Work Product, including any materials derived therefrom or based thereon and regardless of whether any such Work Product is actually used by the Company, shall from its creation be owned exclusively by the Company and Consultant will not have or claim to have any rights of any kind whatsoever in such Work Product. Without limiting the generality of the foregoing, Consultant will not make any use of any of the Work Product in any manner whatsoever without the Company’s prior written consent.

 

6.4.            Representations Regarding Work Product . Consultant represents and warrants that the Work Product provided by it hereunder will be original works created by it or a third party and not previously published in any form and that the use by the Company of the Work Product will not violate or infringe on any copyright or other proprietary or privacy right of any other Person and that the Company will have the right to use the Work Product in perpetuity without obligation to any Person. In the event of any breach of this representation and warranty, Consultant agrees to indemnify the Company and hold it harmless from and against any and all claims, costs, liabilities and expenses incurred by it as a result of such breach. “ Person ” means any individual, corporation, partnership, joint venture, limited liability company, trust, unincorporated organization or governmental entity.

 

 

 

 

 

  6  
 

 

6.5.            Assignment of Rights . In some jurisdictions, Consultant may have a right, title, or interest (“ Right, ” including without limitation all right, title, and interest arising under patent law, copyright law, trade-secret law, or otherwise, anywhere in the world, including the right to sue for present or past infringement) in certain Work Product that cannot be automatically owned by the Company. In that case, if applicable law permits Consultant to assign Consultant’s Right(s) in future Work Product at this time, then Consultant hereby assigns any and all such Right(s) to the Company, without additional compensation to Consultant; if not, then Consultant agrees to assign any and all such Right(s) in any such future Work Product to the Company or its nominee(s) upon request, without additional compensation to Consultant.

 

6.6.            Waiver of Moral Rights . The Consultant waives the Consultant’s moral rights to any and all copyrights subsisting in the Work Product. If required by the Company, the Consultant also agrees to sign, and to cause the Consultant’s employees and subcontractors to sign, any applications or other documents the Company may reasonably request: (a) to obtain or maintain patent, copyright, industrial design, trade-mark or other similar protection for the Work Product, (b) to transfer ownership of the Work Product to the Company, and (c) to assist the Company in any proceeding necessary to protect and preserve the Work Product. The Company will pay for all expenses associated with preparing and filing such documents.

 

ARTICLE VII.
MISCELLANEOUS

 

7.1.            Notices . All notices, approvals, consents, requests, and other communications hereunder shall be in writing and shall be delivered (i) by personal delivery, or (ii) by national overnight courier service, or (iii) by certified or registered mail, return receipt requested, or (iv) via facsimile transmission, with confirmed receipt, or (v) via email. Notice shall be effective upon receipt except for notice via fax (as discussed above) or email, which shall be effective only when the recipient, by return or reply email or notice delivered by other method provided for in this Section 7.1, acknowledges having received that email (with an automatic “ read receipt ” or similar notice not constituting an acknowledgement of an email receipt for purposes of this Section 7.1, or which such recipient ‘replies’ to such prior email). Such notices shall be sent to the applicable party or parties at the address specified below:

 

If to the Company :

Panther Biotechnology, Inc.

Attn: Evan Levine

1517 San Jacinto Street

Houston, Texas 77002

Phone: 858-263-2744

Email: info@pantherbiotechnology.com

 

If to the Consultant:

Rob Estell

4400 Sample Road

Coconut Creek, Florida 33073

Telephone: 561-441-9932

Email: rob@thepoolpros.com

 

 

 

 

 

 

  7  
 

 

7.2.            Binding Effect; Assignment . This Agreement shall be binding upon and inure to the benefit of the Parties and their respective legal representatives, heirs, successors and assigns. Consultant may not assign any of its rights or obligations under this Agreement. The Company may assign its rights and obligations under this Agreement to any successor entity.

 

7.3.            Severability . If any provision of this Agreement, or portion thereof, shall be held invalid or unenforceable by a court of competent jurisdiction, such invalidity or unenforceability shall attach only to such provision or portion thereof, and shall not in any manner affect or render invalid or unenforceable any other provision of this Agreement or portion thereof, and this Agreement shall be carried out as if any such invalid or unenforceable provision or portion thereof were not contained herein. In addition, any such invalid or unenforceable provision or portion thereof shall be deemed, without further action on the part of the Parties hereto, modified, amended or limited to the extent necessary to render the same valid and enforceable.

 

7.4.            Waiver . No waiver by a Party of a breach or default hereunder by the other Party shall be considered valid, unless expressed in a writing signed by such first Party, and no such waiver shall be deemed a waiver of any subsequent breach or default of the same or any other nature.

 

7.5.            Entire Agreement . This Agreement sets forth the entire agreement between the Parties with respect to the subject matter hereof, and supersedes any and all prior agreements between the Company and Consultant, whether written or oral, relating to any or all matters covered by and contained or otherwise dealt with in this Agreement. This Agreement does not constitute a commitment of the Company with regard to Consultant’s engagement, express or implied, other than to the extent expressly provided for herein.

 

7.6.            Amendment . No modification, change or amendment of this Agreement or any of its provisions shall be valid, unless in a writing signed by the Parties.

 

7.7.            Captions . The captions, headings and titles of the sections of this Agreement are inserted merely for convenience and ease of reference and shall not affect or modify the meaning of any of the terms, covenants or conditions of this Agreement.

 

7.8.            Governing Law . This Agreement, and all of the rights and obligations of the Parties in connection with the relationship established hereby, shall be governed by and construed in accordance with the substantive laws of the State of Texas without giving effect to principles relating to conflicts of law.

 

7.9.            Survival . The termination of Consultant’s engagement with the Company pursuant to the provisions of this Agreement shall not affect Consultant’s obligations to the Company hereunder which by the nature thereof are intended to survive any such termination, including, without limitation, Consultant’s obligations under ARTICLE IV of this Agreement.

 

7.10.        No Presumption from Drafting . This Agreement has been negotiated at arm’s-length between persons knowledgeable in the matters set forth within this Agreement. Accordingly, given that all Parties have had the opportunity to draft, review and/or edit the language of this Agreement, no presumption for or against any Party arising out of drafting all or any part of this Agreement will be applied in any action relating to, connected with or involving this Agreement. In particular, any rule of law, legal decisions, or common law principles of similar effect that would require interpretation of any ambiguities in this Agreement against the Party that has drafted it, is of no application and is hereby expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner to affect the intentions of the Parties.

 

 

 

  8  
 

 

7.11.        Review and Construction of Documents . Each Party herein expressly represents and warrants to all other Parties hereto that (a) before executing this Agreement, said Party has fully informed itself of the terms, contents, conditions and effects of this Agreement; (b) said Party has relied solely and completely upon its own judgment in executing this Agreement; (c) said Party has had the opportunity to seek and has obtained the advice of its own legal, tax and business advisors before executing this Agreement; (d) said Party has acted voluntarily and of its own free will in executing this Agreement; and (e) this Agreement is the result of arm’s length negotiations conducted by and among the Parties and their respective counsel.

 

7.12.        Interpretation . When used in this Agreement, unless a contrary intention appears: (i) a term has the meaning assigned to it; (ii) “ or ” is not exclusive; (iii) “ including ” means including without limitation; (iv) words in the singular include the plural and words in the plural include the singular; (v) any agreement, instrument or statute defined or referred to herein or in any instrument or certificate delivered in connection herewith means such agreement, instrument or statute as from time to time amended, modified or supplemented and includes (in the case of agreements or instruments) references to all attachments thereto and instruments incorporated therein; (vi) the words “ hereof ”, “ herein ” and “ hereunder ” and words of similar import when used in this Agreement shall refer to this Agreement as a whole and not to any particular provision hereof; (vii) references contained herein to Article, Section, Schedule and Exhibit, as applicable, are references to Articles, Sections, Schedules and Exhibits in this Agreement unless otherwise specified; and (viii) references to “ writing ” include printing, typing, lithography and other means of reproducing words in a visible form, including, but not limited to email.

 

7.13.        Electronic Signatures and Counterparts . This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .peg or similar attachment to electronic mail (any such delivery, an “ Electronic Delivery ”) shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any Party, each other Party shall re execute the original form of this Agreement and deliver such form to all other Parties. No Party shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such Party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

 

 

 

 

 

 

 

  9  
 

 

IN WITNESS WHEREOF , the Parties hereto have executed this Agreement as of the day and year first above written, to be effective as of the Effective Date.

 

COMPANY

PANTHER BIOTECHNOLOGY, INC.




By: /s/ Evan Levine                                

Its: CEO
Printed Name: Evan Levine

   
   
   
   
CONSULTANT

/s/ Rob Estell                               

ROB ESTELL

 

 

 

  10